Minimal and Maximal Models to Quantitate Glucose Metabolism: Tools to Measure, to Simulate and to Run *in Silico* Clinical Trials

Cobelli C., Ph.D[1] and Dalla Man C., Ph.D[2]

Author Affiliations: [1]Department of Woman and Child's Health University of Padova, Padova, Italy; [2]Department of Information Engineering, University of Padova, Padova, Italy

Claudio Cobelli
Department of Woman and Child's Health,
University of Padova
Via N. Giustiniani, 3
35128 Padova, Italy
cobelli@dei.unipd.it

+39 335 6055945

Chiara Dalla Man
Department of Information Engineering,
University of Padova
Via Gradenigo 6B
35131 Padova, Italy
dallaman@dei.unipd.it

+39 0498277713

Abbreviations: (Ra) glucose rate of appearance, (EGP) endogenous glucose production, (Rd) glucose rate of disappearance, (UVA) University of Virginia, (AP) artificial pancreas, FDA (Food and Drug Administration), (IEEE TBME) IEEE Transactions on Biomedical Engineering, (MTT) mixed meal tolerance test, (OGTT) oral glucose tolerance test, (PET) positron emission tomography, (IVGTT) intravenous glucose tolerance test, (DI) disposition index, (GLP-1) Glucagon-Like Peptide-1, (ISR) insulin secretion rate, (IDR) post-hepatic insulin delivery rate, (HE) hepatic insulin extraction, (SI) insulin sensitivity, (GE) glucose effectiveness, (Φ) beta-cell responsivity, (OMM) oral minimal model, ([^{18}F]FDG) [^{18}F]fluorodeoxyglucose, (LC) lumped constant, (RRP) readily releasable pool, (*TTR*) tracer to tracee ratio, (*GIR*) glucose infusion rate, (T1D) type 1 diabetes, (T2D) type 2 diabetes, ((H) healthy (NIH) National Institute of Health, (sc) subcutaneous, (CGM) continuous glucose monitoring, (SMBG) self-monitoring blood glucose, (JDRF) Juvenile Diabetes Research Foundation, (MPC) model predictive control, (IDE) investigational device exemption, (DirecNet) Diabetes Research in Children Network, (OpenAPS) Open Artificial Pancreas System, (ISCT) in silico clinical trial, (U) glucose utilization.

Corresponding Author: Claudio Cobelli, Department of Woman and Child's Health, University of Padova, Via N. Giustiniani, 3 35128 Padova, Italy email address: cobelli@dei.unipd.it.

Abstract

Several models have been proposed to describe the glucose system at whole-body, organ/tissue and cellular level, designed to measure non-accessible parameters (minimal models), to simulate system behavior and run *in silico* clinical trials (maximal models). Here, we will review the authors' work, by putting it into a concise historical background.

We will discuss first the parametric portrait provided by the *oral minimal models* – building on the classical intravenous glucose tolerance test minimal models – to measure otherwise non-accessible key parameters like insulin sensitivity and beta-cell responsivity from a physiological oral test, the mixed meal or the oral glucose tolerance tests, and what can be gained by adding a tracer to the oral glucose dose. These models were used in various pathophysiological studies, which we will briefly review. A deeper understanding of insulin sensitivity can be gained by measuring insulin action in the skeletal muscle. This requires the use of isotopic tracers: both the classical multiple-tracer dilution and the positron emission tomography techniques are discussed, which quantitate the effect of insulin on the individual steps of glucose metabolism, i.e., bidirectional transport plasma-interstitium, and phosphorylation. Finally, we will present a cellular model of insulin secretion that, using a multiscale modeling approach, highlights the relations between minimal model indices and subcellular secretory events.

In terms of *maximal models*, we will move from a parametric to a flux portrait of the system by discussing the triple tracer meal protocol implemented with the tracer-to-tracee clamp technique. This allows to arrive at quasi-model independent measurement of glucose rate of appearance (Ra), endogenous glucose production (EGP), and glucose rate of disappearance (Rd). Both the fast absorbing simple carbs and the slow absorbing complex carbs are discussed. This rich data base has allowed us to build the UVA/Padova Type 1 diabetes and the Padova Type 2 diabetes large scale simulators. In particular, the UVA/Padova Type 1 simulator proved to be a very useful tool to safely and effectively test *in silico* closed-loop control algorithms for an artificial pancreas (AP). This was the first and unique simulator of the glucose system accepted by the U.S. Food and Drug Administration as a substitute to animal trials for *in silico* testing AP algorithms. Recent uses of the simulator have looked at glucose sensors for non-adjunctive use and new insulin molecules.

1. INTRODUCTION

Since the early history of modeling in physiology and medicine, the glucose system has received considerable attention and has stimulated the development of new modeling methodologies. The last decades have seen a growing attention due to the diabetes pandemic and to important developments in diabetes modeling and technology [1]. Biomedical engineering has allowed important achievements in the areas of technology, modeling, signal processing and control. Here we focus on modeling in the quantitative understanding of the glucose system and its

progressive derangement from prediabetes to type 2 or type 1 diabetes. The formal understanding and description of glucose-insulin metabolism in health and diabetes is, arguably, one of the most advanced applications of modeling in the life sciences, given the rich history of available models.

In this paper we will provide a personal story on advancements of diabetes modeling in the last 20-25 years. It is neither a comprehensive review on all the modeling contributions of the literature nor a review of our work in areas of glucose sensor signals and closed-loop glucose control for which we refer to [1]. However, in Section 2 a concise historical background on some landmark models is provided taken from [2] on the occasion of a special IEEE TBME issue devoted to historical development of methodologies and technologies relevant for biomedical engineering which allows us to put our story in a proper perspective. Even with this personal connotation, we do hope this paper, by collecting contributions appeared in biomedical engineering, physiological and clinical journals, will be useful to the diabetes community, and especially to young investigators entering the field. To allow a deeper insight into the various models, all the material used will be clearly referenced to the original publications.

We will make reference to two classes of models, i.e. *minimal (coarse-grained) –* and *maximal (fine-grained) models*. Minimal models are parsimonious descriptions of key components of system functionality capable of measuring non-accessible parameters of the system, while maximal models are very comprehensive descriptions attempting to fully implement the body of knowledge about the system into a generally large, nonlinear model of high order, with several parameters, allowing to perform simulation and to conduct *in silico* trials.

We will first discuss the *parametric portrait* provided by the *oral minimal models* to measure otherwise non-accessible parameters like *insulin sensitivity* and *beta-cell responsivity* from a physiological oral test, the mixed meal tolerance test (MTT) or the oral glucose tolerance tests (OGTT), and what can be gained by adding a tracer to the oral dose. These models have been used in various pathophysiological studies, which we will briefly describe. Subsequently we will move down in the hierarchical system structure and get a deeper physiological understanding on *insulin action in the skeletal muscle*. We will discuss the classical *multiple tracer dilution technique* and the technique based on *positron emission tomography* (PET), which quantitate the effect of insulin on the individual steps of glucose metabolism, i.e. transport and phosphorylation. Finally, by using a multiscale modeling approach we will highlight the relations between *beta-cell function minimal model indices* and *secretory subcellular events*.

Then, we turn to discuss *maximal models* which allow to arrive at a *flux portrait* of the glucose system. This is a very important qualitative jump in the system description. In fact, assessing the postprandial glucose fluxes may highlight possible defects in how the system coordinates changes in the meal/OGTT glucose rate of appearance *(Ra)*, endogenous glucose production *(EGP)*, and glucose

disposal (*Rd*) leading to postprandial hyperglycemia. Here tracers are not only desirable to get a more detailed portrait but are indispensable.

The tracer theory necessary to arrive at a flux portrait is described in some detail but with an easy language to favor its use in the diabetes community. The gold standard is the *triple tracer meal protocol* implemented with the tracer-to-tracee clamp technique which allows to arrive at quasi-model independent measurement of *Ra, EGP* and *Rd*. While the method was originally proposed for the fast absorbing simple carbs, it has recently been extended to handle the slow absorbing complex carbs: both are discussed in this paper. This rich data base has allowed us to build the *UVA/Padova Type 1 diabetes* and *the Padova Type 2 diabetes large scale simulators*. In particular, the UVA/Padova Type 1 simulator proved to be a very useful tool to safely and effectively test *in silico* trials closed-loop control algorithms of insulin administration (the so called Artificial Pancreas, AP). This is the first and unique simulator of the glucose system accepted by the U.S. Food and Drug Administration as a substitute to animal trials for *in silico* testing AP algorithms. Recent uses of the simulator have looked at glucose sensors for non-adjunctive use and new insulin molecules.

2.   HISTORICAL BACKGROUND: LANDMARK MODELS [2]

A conceptual breakthrough in the characterization of Claude Bernard's milieu interieur was allowed by the introduction of tracers to trace the movement of substances (tracee): Rudolf Schoenheimer in 1942 formulated in a famous book [3] the concept of *dynamic state of body constituents* by which at any time the concentration of a substance in the circulation, e.g. of a substrate or a hormone, is the result of production/secretion, distribution, exchange with other body pools, and utilization/ degradation. The dynamic state of body constituents was a qualitative paradigm and its quantitative into fluxes of production, distribution and metabolism was a difficult problem, especially in vivo. There was the need to develop system dynamic models able to interpret the plasma measurements, and thus tackle problems like model structure determination, model identification and validation. Studies employing radioactive glucose tracers increased in the 1940's, especially after World War 2 when *radioactive isotopes* became commercially available (it took another 30 years to see the first glucose *stable isotope* tracer study in children [4]). The increased number of animal and human tracer studies stimulated the development of modeling methodologies. In 1948 Sheppard introduced for the first time the term *compartment*, and provided the first *multi-compartment model of tracer kinetics* in a steady state tracee system described by a system of linear time-invariant differential equations [5]. Handling linear differential equation models in the 1950s was computationally challenging and feasible only for the two- and some three compartment models. A significant step forward was made possible in the 1960s by the introduction *of analog computers* and, later, by *digital computers* when the first book on compartmental models by Sheppard [6] was published. New momentum in the use of digital computers for modeling metabolic systems was

brought by Mones Berman at NIH, Bethesda, MD [7]. The 60s saw also some important methodological contributions, thanks to the ability of *measuring insulin concentration* in the circulation with radioimmunoassy methods [8]. Berman and Schoenfeld [9] addressed for the first time the a priori identifiability problem for linear compartmental models. Tracer theory was extended to study tracee systems also in non-steady state, i.e. after a perturbation like a meal or physical activity: tracer kinetics is still described by linear differential equations, but parameters become time-variant (as a result of nonlinearity)[10]. Compartmental models moved out of the tracer context and *nonlinear compartmental models* were formalized to describe physiological control systems, e.g. production, distribution, utilization of glucose; secretion, distribution, degradation of insulin, and the feedback glucose and insulin signals. Later, in the 1970/80s, the methodological problems posed by linear, but also nonlinear, compartmental models saw a new cultural wave. The identifiability problem was attacked by various investigators (see the review [11]). The numerical identification of models was posed in the correct theoretical setting with tools including test of residuals, parameter precision and parsimony criteria (see the review [12]) and model validation [13]. Books were published offering a consolidated methodology for modeling endocrine and metabolic systems [14][15][16]. Of note has been the use of Bayesian methods given the increased a priori knowledge that was become available.

Some landmark models are described below.

Glucose fluxes. The tracer method by Steele [17], and, later, the ingenious tracer clamp infusion protocol by Norwich [18] and Radziuk [19] allowed to measure the rate of appearance, Ra, and disappearance, Rd, of glucose in a variety of experimental situations. This approach was later put on more solid theoretical grounds [20]. The increased use of stable glucose isotopes has stimulated the generalization to the tracer-to-tracee clamp technique [21].

Insulin secretion. Measurement of insulin secretion after a glucose stimulus was posed as a classical input estimation problem by deconvolution [22]. However, it is not possible to reconstruct pancreatic secretion from plasma insulin concentration since insulin is degraded by the liver before appearing in the circulation. The problem was bypassed when the hormone C-peptide was discovered since it is secreted equimolarly with insulin, but it is extracted by the liver to a negligible extent [23][24]. The knowledge of C-peptide kinetics requires an additional experiment, but a method was proposed in [25] that allows C-peptide kinetic parameters to be derived in an individual based on subject anthropometric characteristics.

Insulin action. Victor Bolie [26] pioneered the filed by proposing a linear model to describe the plasma glucose and insulin concentrations in an intravenous glucose tolerance test (IVGTT). The model was subsequently extended to an oral glucose tolerance test (OGTT) in [27]. Both these models were simplistic, but at that time plasma insulin was not available and the models were fitted on plasma glucose only. An elegant tracer study by Insel et al. [28] with the glucose system in two steady

states, i.e. basal glucose & basal insulin, and basal glucose & elevated insulin, advanced the field by assessing timing and magnitude of insulin action. Linear three-compartment models were used to describe glucose and insulin kinetics, and in order to describe insulin-dependent glucose utilization, it was necessary to postulate insulin control from a large, slowly equilibrating compartment, thus confirming the finding of a year before by Sherwin et al [29], who showed that it is insulin in a remote compartment that controls glucose utilization. In 1979 Bergman and Cobelli [30] introduced the minimal model to describe an IVGTT, thus arriving at an index of insulin action, called insulin sensitivity, without the use of tracers. We will discuss this model in Section 3 in the context of its extension to an oral test, i.e. a mixed meal tolerance test or an OGTT.

Beta-cell function. Deconvolution allows measuring insulin secretion after a glucose stimulus. However, a mechanistic insulin secretion model is needed to arrive at indices of beta-cell function. The key model was that of Licko [31] who, starting from the cellular insulin secretion model by Grodsky [32], developed a whole-body IVGTT model and proposed beta-cell function indices, i.e. 1st and 2nd phase responsivity. While models based on insulin data allowed post-hepatic insulin delivery to be quantified, an improved parametric portrait was later obtained by a C-peptide IVGTT model [33], which integrates the 1st and 2nd phase secretion model into the two-compartment model of C-peptide kinetics. Since the glucose–insulin system is a negative feedback system, beta-cell function needs to be interpreted in light of the prevailing insulin sensitivity: the *disposition index* (DI) paradigm was introduced in [34] where beta-cell function is multiplied by insulin sensitivity.

Cellular model of insulin secretion. The landmark model was developed by Grodsky [32]. A variety of glucose stimuli in the perfused rat pancreas was the data base. He proposed that insulin was located in "packets", plausibly the insulin containing granules, but possibly entire beta-cells. In this model, part of the insulin is stored in a reserve pool, while other insulin packets belong to a labile and releasable pool. The rapid release of the labile pool results in the first phase of insulin secretion, while the reserve pool is responsible for the sustained second phase. To explain the staircase experiment, where glucose concentration is increased in consecutive steps, he assumed that the packets in the labile pool have different thresholds with respect to glucose beyond which they release their content.

3.   THE ORAL MINIMAL MODELS: INSULIN SENSITIVITY, BETA-CELL RESPONSIVITY and HEPATIC EXTRACTION

For reader convenience/information, most of the material reported in this section is taken from our review [35].

The simultaneous assessment of insulin action, insulin secretion and hepatic extraction is key to understand postprandial glucose metabolism in people with and

without diabetes and to put therapy on solid grounds [1][35][36][37]. Here, we discuss the oral minimal model method [35], i.e. models that allow the estimation of insulin sensitivity, beta-cell function and hepatic insulin extraction from an oral glucose test, either a mixed meal (MTT) or an oral glucose (OGTT) tolerance test. Both these tests are more physiologic and simpler than those based on an intravenous test, (e.g. a glucose clamp or an intravenous glucose tolerance (IVGTT) test), with MTT being superior to OGTT due to the presence of other macronutrients (proteins and fat).

The oral glucose minimal model method sits on the giant shoulders of the IVGTT minimal model [30], particularly taking advantage of two revolutionary concepts introduced in 1979: i) the system is partitioned into a glucose and insulin subsystem, thus allowing modeling of each system using, respectively, plasma insulin and glucose as known inputs; and, ii) insulin control is from a compartment remote from plasma (known today to be interstitium). The IVGTT seems simpler to model since one knows the input, i.e. the glucose dose. However, modeling glucose dynamics after the bolus is complex: the single compartment may undermodel the system with potential bias introduced, e.g. on insulin sensitivity [38]. To improve the quantitation of beta-cell function, a C-peptide IVGTT minimal model has been developed which allows to estimate 1st and 2nd phase beta-cell responsivity [33], and also, in conjunction with the IVGTT insulin minimal model, hepatic insulin extraction [39]. Finally, the IVGTT method does not describe the incretin contribution to insulin secretion.

Historically, the oral minimal model method has been facilitated by triple tracer meal studies done at Mayo Clinic, Rochester, MN (details in, section 7.2.2) which have provided a rich data base for model development and validation [40]. The MTT/OGTT data are shown in Figure 1 (upper panel). The system is partitioned like in Figure 1 (bottom panel). What is the rationale? For instance, to describe plasma glucose and insulin data after an oral glucose test, there is the need to simultaneously model both the glucose and insulin systems and their interactions, i.e. in addition to model insulin action, one also has to model glucose-stimulated insulin secretion. Since by definition models are useful but never true, an error in the insulin secretion model would be compensated by an error in the insulin action model, thus introducing a bias in insulin sensitivity. To avoid this source of error, an artificial "loop cut" decomposes the system in two subsystems which are linked together by measured variables. The measured MTT/OGTT time courses of insulin and glucose can be considered as "input" (known) and "output" (noisy), respectively, to measure insulin sensitivity (Figure 1, bottom panel, top); those of glucose and C-peptide to measure beta-cell function (Figure 1, bottom panel, middle); and those of glucose and insulin plus C-peptide to measure hepatic insulin extraction (Figure 1, bottom panel, below). In this way, models are developed not for the whole system but for each of the subsystems, independently.

Figure 1 shows the recommended MTT/OGTT 10-sample schedule (0,10,20,30,60,90,120,150,180,240 min) but 8-samples (without 150 and 240 min) still provide accurate results in subjects without diabetes at the individual level. If

indices only in large population studies are needed, a 7-sample schedule can be used in subjects without diabetes and with prediabetes [41].
Table 1 summarizes the parameters of the oral minimal method.

3.1 The Glucose Minimal Model

The glucose minimal model is shown in Figure 2 (upper panel). The gastrointestinal tract is the new element with respect to the IVGTT minimal model. Given the smoother oral vs IVGTT time course of plasma glucose and insulin, a single compartment model describes accurately glucose kinetics (while a two compartment model is needed to describe IVGTT in their integrity [38][42]).
Denoting by Q the plasma glucose mass, Rd the rate of plasma glucose disappearance, Ra the rate of glucose appearance in plasma from the oral input and NHGB the net hepatic glucose balance, the model and the measurement equations are:

$$\begin{cases} \dot{Q}(t) = -Rd(t) + NHGB(t) + Ra(t) & Q(0) = Q_b \\ G(t) = \dfrac{Q(t)}{V} \end{cases} \tag{1}$$

where G is plasma glucose concentration, V the glucose distribution volume and suffix b denotes basal value.

By assuming that Rd and NHGB are linearly dependent on Q, but modulated by insulin in a remote (vs plasma) compartment, as proposed in [30], one obtains [43]:

$$\begin{cases} \dot{Q}(t) = -[S_G + X(t)] \cdot Q(t) + S_G \cdot Q_b + Ra(\boldsymbol{\alpha},t) & Q(0) = Q_b \\ \dot{X}(t) = -p_2 \cdot X(t) + p_3 \cdot [I(t) - I_b] & X(0) = 0 \\ G(t) = \dfrac{Q(t)}{V} \end{cases} \tag{2}$$

where S_G is fractional (i.e., per unit distribution volume) glucose effectiveness measuring glucose ability per se to promote glucose disposal and inhibit NHGB, I plasma insulin concentration, X insulin action on glucose disposal and production, with p_2 and p_3 rate constants describing its dynamics and magnitude. Ra is described as a piecewise-linear function with known break-point t_i and unknown amplitude α_i:

$$Ra(\boldsymbol{\alpha},t) = \begin{cases} \alpha_{i-1} + \dfrac{\alpha_i - \alpha_{i-1}}{t_i - t_{i-1}} \cdot (t - t_{i-1}) & for\ t_{i-1} \leq t \leq t_i,\ i=1,...,8 \\ 0 & otherwise \end{cases} \tag{3}$$

with $\boldsymbol{\alpha}$ denoting $[\alpha_1, \alpha_2,...\alpha_8]^T$.
Insulin sensitivity, S_I, is given by:

$$S_I = \frac{p_3}{p_2} \cdot V \quad \text{(dl/kg/min per } \mu\text{U/ml)} \tag{4}$$

A piecewise linear description for Ra with 8 parameters is sufficiently flexible to accommodate MTT/OGTT data. The input is plasma insulin with plasma glucose the output to be fitted by the model. Parameters α render the model not a priori uniquely identifiable because V is non-identifiable and S_G is non-uniquely identifiable. Thus, V and S_G are usually fixed to population values. To improve numerical identifiability, a Maximum a Posteriori Bayesian estimator is used by exploiting some prior on p_2 and a constraint on Ra, related to the total amount of glucose appearing in the circulation. S_I is precisely estimated with good precision and has been validated in a multiple tracer meal protocol [44] and in an OGTT vs euglycemic glucose clamp study [45] showing a correlation of 0.86 and 0.81, respectively. MTT S_I has been correlated with IVGTT S_I in the same subjects with correlation of 0.74. MTT S_I was also compared with OGTT S_I in 62 subjects [46] with a correlation of r=0.75, but S_I was significantly lower in MTT than OGTT.

Inter-subject variability of MTT S_I in healthy individuals is comparable to that of the IVGTT index [47], in particular its reproducibility (expressed as percent mean difference and coefficient of variation) were on average 8% and 23%, respectively.

3.2 The C-peptide Minimal Model

The model is shown in Figure 2 (middle panel): plasma C-peptide concentration is the output with glucose concentration as the input [48].
The model is described by:

$$
\begin{cases}
\dot{q}_1(t) = -(k_{01} + k_{21}) \cdot q_1(t) + k_{12} \cdot q_2(t) + ISR(t) & q_1(0) = 0 \\[2mm]
\dot{q}_2(t) = -k_{12} \cdot q_2(t) + k_{21} \cdot q_1(t) & q_2(0) = 0 \\[2mm]
ISR(t) = y(t) + k_G \cdot \dfrac{dG(t)}{dt} \\[2mm]
\dot{y}(t) = -\dfrac{1}{T}\left[y(t) - \beta \cdot (G(t) - h)\right] & y(0) = 0 \\[2mm]
c_1(t) = \dfrac{q_1(t)}{V}
\end{cases} \tag{5}
$$

where q_1 and q_2 are respectively the above basal amount of C-peptide in the accessible and remote compartment (C-peptide 1 and 2 in Figure 2, middle panel), k_{01}, k_{12} and k_{21} are rate constants describing C-peptide kinetics, ISR is C-peptide (insulin) secretion rate, y is insulin provision (i.e. the portion of synthesized insulin

that reaches the cell membrane and can be released), and c_1 is above basal C-peptide plasma concentration. ISR is made up of two components: one proportional, through parameter k_G, to glucose rate of change (dG/dt), and one representing insulin release that, after a delay T, occurs proportionally to plasma glucose level above a threshold, h, through parameter β. The two components are termed *dynamic*, Φ_d ($=k_G$), and *static*, Φ_s ($=\beta$), *responsivity indices*. A single *total responsivity index*, Φ, which combines Φ_d and Φ_s, is often useful. The model is both a priori and numerically uniquely identifiable once C-peptide kinetic parameters (k_{01}, k_{12} and k_{21}) are fixed using the population model [25]. The picture is markedly different from that of the IVGTT, where the incretin effect is absent and the glucose signal is very different, with the derivative component only contributing during the first 2-3 minutes and the proportional component for the rest of test. This explains the fact that dynamic Φ_d and static Φ_s during an MTT are 250% greater than 1st phase, Φ_1, and 2nd phase, Φ_2, IVGTT indices in the same 204 individuals [40]. Dynamic, Φ_d, and static, Φ_s, during an oral glucose challenge and IVGTT 1st, Φ_1, and 2nd, Φ_2, phase indices bear some relation (r=0.52 for both indices), but they are likely determined by different cellular events.

MTT beta-cell responsivity indices were also compared with their OGTT counterparts in 62 subjects [46] with good correlation, r=0.71 for Φ_d, r=0.73 for Φ_s, r=0.74 for Φ, but the indices were significantly higher in MTT than OGTT.
It is an accepted notion that beta-cell function needs to be interpreted in light of the prevailing insulin sensitivity. One possibility is to resort to the *disposition index* (DI) paradigm, first introduced in 1981 [34], and recently revisited [47][49], where beta-cell function is multiplied by insulin sensitivity. This concept is clearly illustrated in Figure 3 (left panel). It is postulated that glucose tolerance of an individual is related to the product of beta-cell function and insulin sensitivity. In essence, different values of tolerance are represented by different hyperbolas, i.e. DI = beta-cell function x insulin sensitivity = const. The DI was first introduced for IVGTT and has been extended to MTT/OGTT. Thus, disposition indices can be calculated by multiplying responsivity indices Φ_d, Φ_s, Φ by S_I to determine if the first phase, second phase and total beta-cell function are appropriate in light of the prevailing insulin sensitivity. For instance, while S_I was found to be significantly lower in MTT than OGTT and Φ significantly higher in MTT than OGTT, DI was the same, making it a good marker of glucose tolerance [46]. The DI can also monitor in time the individual components of tolerance and assess different therapies (Figure 3, right panel).
However, the glucose-insulin feedback system is more complex than the simple hyperbola paradigm, i.e. a more general DI could be DI = beta-cell function $\times$ (insulin sensitivity)$^\alpha$ = constant, where insulin sensitivity is raised
to α. In addition, this simple concept hides several methodological issues addressed in [49], which, unless fully appreciated, could lead to errors in interpretation.

MTT Φ_d and Φ_s reproducibility was assessed in [47]: percent mean difference was 1% and 7% and coefficient of variation was 31% and 18%, respectively.
An important addition to the MTT/OGTT parametric portrait is an index quantifying the effect of Glucagon-Like Peptide-1 (GLP-1) - a surrogate for the

incretin effect [50]- on insulin secretion [51]. This extension of the model accounting for the effect of exogenous GLP-1 infusion on insulin secretion was developed in [52]. In particular, the model [52] assumed that the above basal insulin secretion rate, ΔSR, is linearly modulated by GLP-1, through the GLP-1 sensitivity index π (% per pmol/l):

$$\Delta \text{SR}^{\text{GLP1}}(t) = \Delta \text{SR}(t) \cdot [\pi \cdot \text{GLP1}(t) + 1] \tag{6}$$

where GLP1(t) is the above basal intact hormone concentration.
π quantifies the ability of GLP-1 to enhance the over-basal insulin secretion, and is defined as the ratio between the average percent increase in over-basal insulin secretion and average GLP-1 plasma concentration.

3.3 The Insulin & C-peptide Minimal Model

Minimal models can also assess hepatic insulin extraction (Figure 2, bottom panel). Insulin secretion, ISR, can be assessed from the C-peptide model. Similarly, post-hepatic insulin delivery, IDR, can be assessed by employing an insulin model. In [53] an insulin population model (along the line of [25]), allows to calculate insulin kinetic parameters from subject anthropometric characteristic in a population of subjects without diabetes. The model allows to reconstruct IDR. From ISR and IDR, both the time course of hepatic insulin extraction and an index numerically quantifying hepatic insulin extraction can be calculated:

$$HE(t) = \frac{ISR(t) - IDR(t)}{ISR(t)} = 1 - \frac{IDR(t)}{ISR(t)} \tag{7}$$

$$HE = \frac{\int_0^T ISR(t) - \int_0^T IDR(t)}{\int_0^T ISR(t)} = 1 - \frac{\int_0^T IDR(t)}{\int_0^T ISR(t)} \tag{8}$$

with T duration of the experiment.
The importance of adding HE to S_I and Φ for obtaining a more complete parametric portrait has been shown in several studies, e.g. [54][55].

3.4 Models at work in diabetes

The battery of oral glucose, C-peptide and insulin models have been used to study the effect of age and gender on glucose metabolism [40]; the effect of anti-aging drugs [54]; the influence of ethnicity [55][56]; insulin sensitivity and beta-cell function in people without diabetes [57] and obese [58][59] adolescents, and children [59]; the pathogenesis of prediabetes [46][60][61] and type 2 diabetes [36][62]; the diurnal pattern of insulin action and secretion in healthy [63] and type 1 diabetes [64]; the mechanism of insulin resistance in pregnancy [65]; the effect of DPP4 inhibitors on insulin secretion [66]; the effect of a bile acid sequestrant [67]; caloric restriction [68][69]; vagal nerve blockage [70]; genetic variation [71][72][73]; biliopancreatic diversion [74][75]; Roux-en-Y gastric bypass

[76][77]; circadian misalignement [78][79]; oxytocin [80], and antidiabetic drugs [81] on insulin secretion and action.

4. INSULIN ACTION DISSECTED BY TRACER MODELING INTO PERIPHERY AND LIVER

For reader convenience/information, most of the material reported in this section is taken from our review [35] and a chapter of [82].

If the oral glucose load is labelled with a glucose tracer (t), the exogenous glucose (G_{exo}), i.e. the glucose concentration due to meal/OGTT only, can be calculate as:

$$G_{exo}(t) = t(t) \cdot \left(1 + \frac{1}{TTR_{meal}}\right) \qquad (9)$$

where TTR_{meal} is the tracer-to-tracee ratio in the meal/OGTT.

The endogenous glucose (G_{end}) can then be derived as $G_{end} = G - G_{exo}$, with G being the total glucose in plasma. In other words adding a tracer to the MTT/OGTT allows total glucose concentration to be segregated into its exogenous and endogenous components.

4.1 Disposal Insulin Sensitivity

G_{exo} measured in plasma is the result of the glucose rate of appearance coming from the MTT/OGTT, Ra, and the rate of glucose disposal, Rd (Figure 4). Thus, by fitting the model detailed in [83] on G_{exo} and insulin one can estimate both Ra and disposal insulin sensitivity S_I^D, i.e. the ability of insulin to enhance glucose utilization. The model equations are:

$$\begin{cases} \dot{G}_{exo}(t) = -\left[S_G^D + X^D(t)\right] \cdot G_{exo}(t) + \dfrac{Ra(t, \boldsymbol{\alpha})}{V} & G_{exo}(0) = 0 \\ \dot{X}^*(t) = -p_2^D \cdot X^D(t) + p_3^D \cdot \left[I(t) - I_b\right] & X(0) = 0 \end{cases} \qquad (10)$$

where S_G^D is fractional glucose effectiveness measuring glucose ability per se to promote glucose disposal, X^D insulin action on glucose disposal, with p_2^D and p_3^D rate constants describing respectively its dynamics and magnitude. *Disposal insulin sensitivity* is defined as:

$$S_I^D = \frac{p_3^D}{p_2^D} \cdot V \quad \text{(dl/kg/min per } \mu\text{U/ml)} \qquad (11)$$

Ra is that already described for OMM (eq. 3).

The model has been validated first by comparing estimated Ra with a model-independent profile estimated with a multiple tracer experiment (Ra^{ref}, see Section 7.2.2) and S_I^D both with the same index obtained with the hot IVGTT minimal model [84] fed with the model-independent Ra^{ref} [83] and with the disposal insulin sensitivity derived from labelled clamp [45]. Correlation between S_I^D with disposal insulin sensitivity measured with the tracer enhanced euglycemic-hyperinsulinemic clamp technique was r=0.70 [45].

4.2 Liver insulin sensitivity

Theoretically, by using the unlabelled and labelled models to measure, respectively, total (i.e. periphery +liver) and peripheral indices, one should be able to calculate liver indices from the difference between the two.

However, liver indices derived in this way are often unreliable (negative). This was found also during an IVGTT using the classic minimal model [38][84][85][86]. Caumo et al. [38] suggested that these inconsistencies were to an inaccurate description of glucose and insulin effect on *EGP*. In fact, both the IVGTT and the oral minimal models assume that insulin action on the liver has the same time course of insulin action on glucose disposal. Moreover, *EGP* suppression includes a term linearly dependent on glucose and a term equal to the product of glucose concentration and insulin action, i.e. insulin action on the liver is glucose-mediated. The minimal model *EGP* and alternative *EGP* descriptions have been assessed against virtually model-independent EGP profiles [87][88] and liver insulin sensitivity (S_I^L) and glucose effectiveness (GE^L) were estimated.

According to [88], *EGP* can be described as:

$$EGP(t) = EGP_b - k_G \cdot \left[G(t) - G_b\right] - X^L(t) - X^{Der}(t) \qquad EGP(0) = EGP_b \qquad (12)$$

where EGP_b is basal endogenous glucose production, k_G is liver glucose effectiveness.

X^L is liver insulin action, defined as:

$$\begin{cases} \dot{X}^L(t) = -k_1 \cdot X^L(t) + k_1 \cdot X'(t) & X^L(0) = 0 \\ \dot{X}'(t) = -k_1 \cdot \left[X'(t) - k_2 \cdot \left(I(t) - I_b\right)\right] & X'(0) = 0 \end{cases} \qquad (13)$$

with k_1 accounting for the delay of liver insulin action vs plasma insulin, and k_2 a parameter governing its efficacy. X^{Der} is a surrogate of portal insulin, which anticipates insulin and glucose patterns, and was demonstrated to significantly improve model ability to fit the rapid suppression of *EGP* occurring immediately after a meal:

$$X^{Der}(t) = \begin{cases} k_{GR} \cdot \dfrac{dG(t)}{dt} & if \quad \dfrac{dG(t)}{dt} \geq 0 \\ 0 & if \quad \dfrac{dG(t)}{dt} < 0 \end{cases} \qquad (14)$$

where k_{GR} is a parameter governing the magnitude of glucose derivative control.

An index of *liver insulin sensitivity* (S_I^L) can be derived from model parameters as follows:

$$S_I^L = -\left.\frac{\partial EGP}{\partial I}\right|_{ss} \cdot \frac{1}{G_b} = \frac{k_2}{G_b} \qquad (15)$$

where the symbol $|_{ss}$ indicates that the derivative of *EGP* is calculated in steady state.

The model has been first assessed in healthy subjects [88]. Then, it was validated by comparing S_I^L with liver insulin sensitivity measured with a tracer enhanced

euglycemic-hyperinsulinemic clamp (S_I^{Lclamp}) in subjects with different degrees of glucose tolerance [89]. S_I^{Lclamp} is derived from total and peripheral indices as:

$$S_I^{L\,clamp} = S_I^{clamp} - S_I^{*\,clamp} \qquad (16)$$

Correlation between S_I^{Lclamp} and S_I^L was good (r=0.72, p<0.0001), with S_I^{Lmeal} being lower than S_I^{Lclamp} (4.60±0.64 vs 8.73±1.07 10^{-4} dl/kg/min per µU/ml, p<0.01). It is noteworthy that the correlation improved to 0.80, p<0.001 in normal fasting glucose subjects, while it was lower in impaired fasting glucose subjects (r=0.56, p=0.11, likely due to the limited sample size).

4.3 The Single Tracer Oral Minimal Model

The new model describing *EGP* suppression after a meal has been incorporated into the oral glucose minimal model to see if S_I^L could be obtained from plasma concentrations measured after a single-tracer meal by describing both glucose production, P, and disposal, D (OMM^{PD}) [90].

Triple-tracer meal data of two databases (20 healthy and 60 subjects without diabetes and with prediabetes) were used in which a virtually model-independent EGP estimate was available (see Section 7.2.2). OMM^{PD} was identified on exogenous and endogenous glucose concentrations, providing indices of S_I^L, S_I^D and EGP time course.
The estimated S_I^L well compared with that derived directly from EGP data [88]. Since the model is not able to assess basal EGP (EGP$_b$), only the ratio (EGP/EGP$_b$) can be estimated together with S_I^L and S_I^D.

5. MULTISCALE GLUCOSE TRACER MODELING: INSULIN ACTION on SKELETAL MUSCLE PROCESSES

For reader convenience/information, most of the material reported in this section is taken from our review [1].

While whole-body models can provide important quantitative information on insulin action, it is important but at the same time remarkably difficult, to noninvasively measure the effect of insulin on glucose transport and metabolism at the organ level. A crucial target tissue of glucose metabolism is the skeletal muscle. Impaired insulin action in muscle is a well-recognized characteristic of a number of metabolic diseases, including type 2 diabetes, obesity, hypertension, and cardiovascular disease. Understanding its causes requires to segregate and quantify in situ the major individual steps of glucose processing, particularly those of glucose delivery, transport in and out of the cell, and phosphorylation (Figure 5).

The classical experimental approach is based on the *multiple tracer dilution* [91] [91], which consists of the simultaneous injection, upstream of the organ, of more than one tracer to allow the separate monitoring of the individual steps of glucose

metabolism. In the 2000s, the *positron emission tomography* (PET) noninvasive imaging technique was proposed which can provide highly specific and rich biochemical information if applied in dynamic mode, i.e., sequential tissue images acquired following a bolus injection of tracer.

Multiple tracer dilution data can be interpreted with both linear distributed parameter (see reviews [16] and [92]) and compartmental organ models [93]. The only application to glucose metabolism of distributed parameter models has been in an isolated and perfused heart [91]. In contrast, compartmental organ models have been more intensively applied to interpret multiple tracer dilution data in the human skeletal muscle. A compartmental model has been proposed [94][95] describing the transmembrane transport of glucose, i.e. into and out of the cell. This model has been extended [96] to describe the kinetics of a third tracer, permeant nonmetabolizable, thus allowing to quantify not only the rate constants of transport and phosphorylation, but also the bidirectional glucose flux through the cell membrane, the phosphorylation flux, and the intracellular concentration, in subjects with and without diabetes and obese [97][98]. This allowed to show that insulin control on both transmembrane transport and phosphorylation flux in subjects with diabetes is much less efficient with respect to subjects without diabetes.

PET data can be analyzed by regional compartmental modeling. The brain glucose model by Sokoloff et al. [99] has been a landmark. The selected tracer for studying glucose metabolism in skeletal muscle (but also in the brain and myocardium) is [18F] fluorodeoxyglucose ([18F]FDG), a glucose analog. The ideal tracer would be [11C –glucose], but the interpretative model by having to account for all metabolic products along the glycolysis and glycogenosynthesis pathways cannot be resolved. The advantage of [18F]FDG is that a simpler model can be adopted. In fact, [18F]FDG once in the tissue, similarly to glucose, can either be transported back to plasma or can be phosphorilated to [18F]FDG-6-phosphate, [18F]FDG-6-P. The advantage is that [18F]FDG-6-P is trapped in the tissue and released very slowly. In other words, [18F]FDG-6-P cannot be metabolized further, while glucose-6-P does so along the glycolysis and glycogenosynthesis pathways. The major disadvantage of [18F]FDG is the necessity to correct for the differences in transport and phosphorylation between the analog [18F]FDG and glucose. A correction factor called lumped constant (LC) can be employed to convert [18F]FDG fractional uptake (but not the [18F]FDG transport rate parameters) to that of glucose. LC values in human skeletal muscle are available [100][101]. The interpretative model is a four-compartment model (plasma, extracellular, tissue [18F]FDG, and [18F]FDG-6-phosfate) with five rate constants [102]. The model (Figure 6) is described by:

$$\dot{C}_c(t) = K_1 C_p(t) - (k_2 + k_3)C_c(t) + k_4 C_e(t) \qquad C_c(0) = 0$$
$$\dot{C}_e(t) = k_3 C_c(t) - (k_4 + k_5)C_e(t) \qquad C_e(0) = 0$$
$$\dot{C}_m(t) = k_5 C_e(t) \qquad C_m(0) = 0 \qquad (17)$$

$$C(t) = (1 - V_b)\big(C_c(t) + C_e(t) + C_m(t)\big) + V_b C_b(t)$$

where C_p is [18F]FDG plasma arterial concentration, C_c is extracellular concentration of [18F]FDG normalized to tissue volume, C_e [18F]FDG is tissue concentration, C_m [18F]FDG-6-P is tissue concentration, C total 18F is activity concentration in the ROI, K_1 [ml/ml/min] and k_2 [min^{-1}] are the exchanges between plasma and extracellular space, k_3 [min^{-1}] & k_4 [min^{-1}] are the rates of transport in and out of cell, and k_5 [min^{-1}] is the rate of phophorylation. V_b is the fractional blood volume in the region of interest, and C_b is the whole blood tracer concentration. From the model one can calculate the fractional uptake of [18F]FDG, K [ml/ml/min]:

$$K = \frac{K_1 k_3 k_5}{k_2 k_4 + k_2 k_5 + k_3 k_5} \tag{18}$$

and, by using LC value and the glucose basal plasma concentration value, the glucose fractional uptake. .

To move from FDG to glucose, a multi-tracer PET method is needed [103], which allows the simultaneous assessment of blood flow, glucose transport, and phosphorylation in the skeletal muscle. The method employs three different PET tracers (Figure 7) injected at different times, and allows to quantify blood flow from [15O]H$_2$O images with one- compartment two-rate constant model; glucose transport from [11C]3-OMG images with a three compartment four-rate constant model, and, finally, glucose phosphorylation by combining [18F]FDG fractional uptake with [11C]3-OMG rate constants. The [11C]-3-OMG model is a simpler version of that of Eqs 17, since [11C]3-OMG is not phosphorylated. This multi-tracer model has provided important insight on insulin action on muscle unit processes; in particular, it was shown that: glucose transport from plasma into interstitial space is not affected by insulin; insulin significantly increases both glucose transport and phosphorylation; predominately oxidative muscles (soleus) have higher perfusion and higher capacity for glucose phosphorylation than less oxidative muscles (tibialis).

6.   MULTISCALE INSULIN MODELING: INSIGHT into SECRETORY CELLULAR EVENTS

For reader convenience/information, most of the material reported in this section is taken from our review [2].
The models of beta-cell function provide a quantitative assessment of beta-cell function at the whole-body level. To gain a mechanistic insight into the cellular phenomena responsible for insulin secretion, one has to move down in the hierarchical system structure.
The starting point is the landmark model by Grodsky [32] (Figure 8, left panel), briefly described in Section 2, and updates of this model based on data of cell-to-

cell heterogeneity with respect to their activation threshold [104] and Ca^{2+} imaging experiments [105][106]. This new subcellular model [107] describes the dynamics of granule pools in the entire pancreatic population of beta-cells (Figure 8, right panel). Granules mobilize from a reserve pool to a pool of "docked" granules at the plasma membrane. The granules can mature further (priming) to gain release competence and enter the "readily releasable pool" (RRP). Calcium influx then triggers exocytosis and insulin release from the RRP. RRP is heterogeneous, i.e. only granules residing in cells with a threshold for calcium activity below the ambient glucose concentration are allowed to fuse. Thanks to RRP heterogeneity, the model can describe all the classical glucose stimuli, including staircase glucose infusion protocol.

Using multiscale modeling the relation between the beta-cell function minimal model indices and the subcellular events described in the mechanistic model have been investigated [108]. Both the oral and the IVGTT minimal secretion models can be interpreted in the light of this cellular model. The analysis revealed that the *first-phase IVGTT* and the *dynamic oral* secretion both reflect the amount of readily releasable insulin, but also that the dynamic secretion is shaped by the threshold distribution for cell activation as well as the dynamics of mobilization and docking. *Second phase IVGTT* and *static oral* secretion reflect a combination of mobilization, docking, priming and recruitment of new cells. A first attempt to a better understanding of the mechanistic effects of incretins was done in [109] by including GLP-1 in the oral minimal model.

7. A FLUX PORTRAIT OF THE GLUCOSE SYSTEM: TRACERS to MEASURE SIMPLE and COMPLEX CARBOHYDRATE POSTPRANDIAL METABOLISM

Measuring the postprandial glucose turnover is not easy [110]. At variance with the fasting state, after a meal, glucose concentration is not in steady state and is the results of Ra_{meal}, EGP, and Rd pattern.

The first attempt to solve this difficult task was that of Steele et al. [111]. They proposed to label the ingested glucose with one glucose tracer and intravenously infusing a second tracer at a constant rate. Unfortunately, subsequent studies have shown that although this approach is technically simple, the marked changes in plasma tracer-to-tracee ratio, if stable tracers are used, or specific activity, if a radioactive tracer is used, introduce a substantial error in the calculation of *Ra_{meal}*, *EGP,* and *Rd*, thereby leading to incorrect and at times misleading results [112]. This is due to the so called *nonsteady state error*, which is very pronounced after a meal perturbation if the tracer is infused constantly. To minimize such error, Basu and coworkers have proposed a more complex experimental technique called the *triple tracer method,* presented later in this paragraph, which implements the so called *tracer-to-tracee clamp technique* [87].

The theory behind the two techniques is described in detail below.

When the system is in steady state, the rate of glucose entering the circulation (*Ra*) equals the rate of glucose leaving the system (*Rd*). If one starts to infuse the glucose

tracer at a constant rate (*INF*), after a while, also the tracer will be in steady state, and so is also the tracer (*g*) to tracee (*G*) ratio (*TTR=g/G*).

It can easily been shown that one has:

$$Ra \ = \ Rd \ = \frac{INF}{g_{ss}V} G_{ss}V = \frac{INF}{TTR} \qquad (19)$$

In other words, the estimate of *Ra* and *Rd* is model-independent.

In case of food ingestion, the estimation of *Ra* and *Rd* becomes more difficult. First, *Ra* and *Rd* are no longer equal and both are changing over time, resulting in a nonconstant *TTR*. In addition, *Ra* now equals the sum of Ra_{meal} and *EGP*, which are also changing with time [110].

In this case, one needs to specify both the structure (one compartment, two compartment, multi-compartment…) and which parameters are time-varying and these choices have an impact on the glucose fluxes estimate.

For the glucose system the most popular assumptions are that the model is a one- [111] or a two-compartment [19] model and that the time-varying parameter is the fractional clearance rate, since it is known that it is controlled by insulin concentration, which is likely to vary after a meal.

7.1 The intravenous glucose infusion case

For sake of simplicity, let first consider the simpler case of exogenous glucose intravenous infusion (*GIR*), instead of a meal, so that *GIR* is known and only *EGP* and *Rd* have to be estimated. In other words, one will estimate *Ra(t)=GIR(t)+EGP(t)* and then calculate *EGP(t)* by subtracting the known *GIR(t)* from the estimated *Ra(t)*. *Rd(t)* will be then calculated from the model using the mass balance equation. Let also start with a single compartment description with time-varying fractional clearance rate (*k(t)*) proposed by Steele et al [111].

Given that the system is not in steady state, the model of the tracee is:

$$\begin{cases} \dot{Q}(t) = Ra(t) - Rd(t) = Ra(t) - k(t)Q(t) & Q(0) = Q_{ss} = G_{ss}V \\ G(t) = \frac{Q(t)}{V} \end{cases} \qquad (20)$$

Thanks to the tracer-to-tracee indistinguishability principle, one has:

$$\begin{cases} \dot{q}(t) = INF - rd(t) = INF - k(t)q(t) & q(0) = 0 \\ g(t) = \frac{q(t)}{V} \end{cases} \qquad (21)$$

The fractional clearance rate *k(t)* is derived from equation 21:

$$k(t) = \frac{INF}{q(t)} - \frac{\dot{q}(t)}{q(t)} \tag{22}$$

By substituting *k(t)* of eq 22 into eq. 20 and rearranging it, one obtains:

$$Ra(t) = \frac{INF}{TTR(t)} - \frac{q(t)}{TTR(t)} \cdot \frac{dTTR(t)}{dt} = \frac{INF}{TTR(t)} - \frac{g(t)}{TTR(t)} V \cdot \frac{dTTR(t)}{dt} \tag{23}$$

where we have used the relationship $TTR(t) = \frac{g(t)}{G(t)} = \frac{q(t)}{Q(t)}$.

Steele et al. [113] realized that *TTR* measured in the plasma does not represent that in the liver, interstitial fluid, and other compartments. To circumvent this problem, they used a nonhomogenous compartment model and assumed that the "effective" volume was only a fraction of the total body volume of distribution of glucose *V*, indicated as *pV*, with p ranging from 0.5 to 0.8 [114][115][116]:

$$Ra(t) = \frac{INF}{TTR(t)} - \frac{g(t)}{TTR(t)} pV \cdot \frac{dTTR(t)}{dt} \tag{24}$$

EGP and *Rd* are then calculated as:

$$EGP(t) = Ra(t) - GIR(t) \tag{25}$$

$$Rd(t) = Ra(t) - \dot{Q}(t) = Ra(t) - pV\dot{G}(t) \tag{26}$$

On the other hand, if one assumes that the system is described by a two compartment model and that only $k_{01}(t)$ is a time-varying parameter [19], one has:

$$\begin{cases} \dot{Q}_1(t) = Ra(t) - [k_{01}(t) + k_{21}]Q_1(t) + k_{12}Q_2(t) & Q_1(0) = Q_{ss} = G_{ss}V \\ \dot{Q}_2(t) = k_{21}Q_1(t) - k_{12}Q_2(t) & Q_2(0) = G_{ss}V\frac{k_{21}}{k_{12}} \\ G(t) = \frac{Q_1(t)}{V} \end{cases} \tag{27}$$

and the tracer model is:

$$\begin{cases} \dot{q}_1(t) = INF - [k_{01}(t) + k_{21}]q_1(t) + k_{12}q_2(t) & q_1(0) = 0 \\ \dot{q}_2(t) = k_{21}q_1(t) - k_{12}q_2(t) & q_2(0) = 0 \\ g(t) = \frac{q_1(t)}{V} \end{cases} \qquad (28)$$

Paralleling what done for Steele et al model, if one derives $k_{01}(t)$ from eq 28 and substitute it into 27, one obtains:

$$Ra(t) = \frac{INF}{TTR(t)} - \frac{g(t)}{TTR(t)} V \cdot \frac{dTTR(t)}{dt} + k_{21}\left(\frac{q_2(t)}{TTR(t)} - Q_2(t)\right) \qquad (29)$$

where $TTR(t) = \frac{g(t)}{G(t)} = \frac{q_1(t)}{Q_1(t)}$.

EGP is then calculated as in eq. 25, while Rd, according to the two-compartment model, is:

$$Rd(t) = Ra(t) - \dot{Q}(t) = Ra(t) - pV\dot{G}(t) - k_{21}G(t)V + k_{12}Q_2(t) \qquad (30)$$

By comparing eqs 24 and 29, it is evident that the estimate of *Ra(t)* is model-dependent and so are *EGP(t)* and *Rd(t)*. One can argue that the accuracy of the flux estimate can be improved by postulating increasingly complex models (e.g., those that account for differences in the rates of equilibration of glucose and onset of action of insulin in the liver, muscle, and various other tissues in people with or without diabetes). However, the increased complexity of the model has to be balanced against increased difficulty in accurately identifying model parameters.

Luckily, looking at eqs 24 and 29, it is also clear that the closer is *TTR(t)* to a constant (clamped *TTR*) the smaller are the second term in eq 24 and the second and third terms in eq. 29. Therefore, the maintenance of *TTR* in steady state by an appropriate tracer experiment design enables a quasi model-independent measurement of *Ra(t), EGP(t),* and *Rd(t)*.

The question now become: is there a smart way to infuse the tracer so that *TTR* becomes virtually constant?

The answer is yes: since *TTR* is the ratio between the infused tracer and the total glucose concentration, the better way to clamp *TTR* is to infuse the tracer by mimicking the expected pattern of *Ra(t)*, i.e. constantly infusing the tracer before

the exogenous infusion starts, following the expected pattern EGP thereafter, and labeling GIR.

7.2 The mixed meal (MTT) and the oral glucose (OGTT) tolerance test.

In the case of an unknown exogenous input, e.g. during an MTT or an OGTT, one needs at least one tracer mixed with the meal (oral load) to segregate exogenous from endogenous glucose in plasma and another tracer to be infused intravenously to calculate $k(t)$, in case of Steele et al. [111] model, or $k_{01}(t)$ in case of Radziuk [19] model. This minimal configuration is called the *dual tracer method.*

7.2.1 The dual tracer method

Let's call tracer1 (t_1) the tracer mixed in the meal, with a *TTR* in the meal equal to TTR_{meal}, and tracer2 (t_2) the tracer infused intravenously with a constant rate (Figure 9, left panel).

Exogenous glucose (G_{exo}), both labeled and unlabeled, can be derived from t_1 concentration and TTR_{meal}:

$$G_{exo}(t) = t_1(t) \cdot \left(1 + \frac{1}{TTR_{meal}}\right) \tag{31}$$

Endogenous glucose (G_{end}) is derived by subtracting exogenous and i.v. infused tracer concentration (in case of a stable isotope) from total glucose (G):

$$G_{end}(t) = G(t) - G_{exo}(t) - t_2(t) \tag{32}$$

Let now define $TTR_{exo}(t) = \frac{t_2(t)}{G_{exo}(t)}$ and $TTR_{end}(t) = \frac{t_2(t)}{G_{end}(t)}$, then meal rate of appearance Ra_{meal} and *EGP* can be derived with Steele equation as:

$$Ra_{meal}(t) = \frac{INF(t)}{TTR_{exo}(t)} - pV \frac{t_2(t)}{TTR_{exo}(t)} \cdot \frac{dTTR_{exo}(t)}{dt} \tag{33}$$

$$EGP(t) = \frac{INF(t)}{TTR_{end}(t)} - pV \frac{t_2(t)}{TTR_{end}(t)} \cdot \frac{dTTR_{end}(t)}{dt} \tag{34}$$

or with Radziuk equation as:

$$Ra_{meal}(t) = \frac{INF(t)}{TTR_{exo}(t)} - pV \frac{t_2(t)}{TTR_{exo}(t)} \cdot \frac{dTTR_{exo}(t)}{dt} + k_{21}\left(\frac{q_2(t)}{TTR_{exo}(t)} - Q_2(t)\right) \tag{35}$$

$$EGP(t) = \frac{INF(t)}{TTR_{end}(t)} - pV \frac{t_2(t)}{TTR_{end}(t)} \cdot \frac{dTTR_{end}(t)}{dt} + k_{21}\left(\frac{q_2(t)}{TTR_{end}(t)} - Q_2(t)\right) \quad (36)$$

It is intuitive, but it has also be proven experimentally **Errore. L'origine riferimento non è stata trovata.**, that it is impossible to clamp both TTR_{exo} and TTR_{end}, since $Ra_{meal}(t)$ is expected to first increase and than decrease, while $EGP(t)$ is expected to first decrease and then increase.

7.2.2 The triple tracer method

The *triple tracer method* [87]**Errore. L'origine riferimento non è stata trovata.**implements the TTR clamp technique to keep the appropriate plasma *TTRs* constant following glucose ingestion [112]. However, instead of infusing labeled glucose at a constant rate, it varies the intravenous infusion rates of two different tracers in a manner that mimics the anticipated Ra_{meal} and EGP (Figure 9, right panel), so that the changes in the plasma *TTRs* are minimized (Figure 10).

Briefly, let's call tracer1 (t_1) the tracer mixed in the meal, with a *TTR* in the meal equal to TTR_{meal}, tracer2 (t_2) the tracer infused intravenously to mimic the expected pattern of *EGP* and tracer3 (t_3) the tracer infused intravenously to mimic the expected pattern of Ra_{meal}.

Exogenous glucose (G_{exo}), both labeled and unlabeled, can be derived from t_1 concentration and TTR_{meal} as reported in eq 31.

Endogenous glucose (G_{end}) is derived by subtracting exogenous and the i.v. infused tracers concentration (in case both are stable isotopes) from total glucose (G):

$$G_{end}(t) = G(t) - G_{exo}(t) - t_2(t) - t_3(t) \quad (37)$$

Let's now define two *TTRs*: $TTR_{exo}(t) = \frac{t_3(t)}{G_{exo}(t)}$ and $TTR_{end}(t) = \frac{t_2(t)}{G_{end}(t)}$.

EGP can be derived with equations 34 or 36, while Ra_{meal} is calculated as:

$$Ra_{meal}(t) = \frac{INF(t)}{TTR_{exo}(t)} - pV \frac{t_3(t)}{TTR_{exo}(t)} \cdot \frac{dTTR_{exo}(t)}{dt} \quad (38)$$

or, with Radziuk equation, as:

$$Ra_{meal}(t) = \frac{INF(t)}{TTR_{exo}(t)} - pV \frac{t_3(t)}{TTR_{exo}(t)} \cdot \frac{dTTR_{exo}(t)}{dt} + k_{21}\left(\frac{q_2(t)}{TTR_{exo}(t)} - Q_2(t)\right) \quad (38)$$

It is worth noting that this method requires a priori knowledge of the temporal pattern of change of Ra_{meal} and EGP. Such knowledge can be relatively easily gained by conducting a few pilot studies and modifying tracer infusion rate (if necessary), so as to minimize the change in plasma $TTRs$.

The triple tracer method has been presented in [87], and successfully used to assess glucose turnover in elderly vs young subjects and men vs women [40], in untreated [62] and treated type 2 diabetes [36], to assess circadian variation in glucose both in healthy [63] and type 1 diabetes [64]. In all these studies, the oral load consisted of a mixed meal (a jello containing dextrose, proteins and fats) labeled with the stable isotope [1-^{13}C]-glucose and the intravenously infused tracers were the stable isotope [6,6-^{2}H$_2$]-glucose and the radioactive [6-^{3}H]-glucose. The use of the tritium as third tracer simplified the preelaboration of the data, since specific activity can be directly used instead of TTR in the above equations. However, the use of radioactive tracer is not allowed in children and adolescents, thus, the methodology was successfully implemented in adolescents using three stable isotopes ([6,6-^{2}H$_2$]-glucose orally administered with an OGTT, [1-^{13}C]-glucose i.v. infused to mimic Ra_{meal} and [U-^{13}C$_6$]-glucose i.v. infused to mimic EGP) [118].

Recently, the triple tracer technique was extended to assess glucose turnover after meals containing complex, instead of simple, carbohydrates [119]. The natural enrichment of [^{13}C]polysaccharide in some commercially available grains (e.g. Madagascar pink rice and sorghum) was exploited to trace the meal, while [6,6-^{2}H$_2$]-glucose and the [6-^{3}H]-glucose were intravenously infused in healthy volunteers. As expected, both Ra_{meal}, EGP and Rd significantly differed between complex and simple carbohydrate containing meals, highlighting that the use of the simple carbohydrate glucose as the carbohydrate source in triple tracer studies may limit the translational applicability of the results since every day's life meals typically contain complex carbohydrates.

8.   MAXIMAL MODELS FOR *IN SILICO* TRIALS: THE UVA/PADOVA TYPE 1 AND THE PADOVA TYPE 2 SIMULATORS

For reader convenience/information, part of the material reported in this section is taken from [120] and [121].

In Silico Clinical Trials (ISCT) are defined as "The use of individualized computer simulation in the development or regulatory evaluation of a medicinal product, medical device, or medical intervention" [120]. The keyword is "individualized". The idea is to recreate the concept of in vivo trial using an *in silico* approach, where a large number of individual patients is modeled by initializing a disease/intervention model with quantitative information either measured on an individual (subject-specific model), or sampled from population distributions of those values (population-specific model). As discussed in [120], realistic ISCTs

necessitate the availability of a cohort of *in silico* subjects spanning the variability observed in the study population, i.e. an average model is useless.

After years of rejection, some regulators are now beginning to consider a possible role for computer modeling and simulation in the certification process for biomedical products. The United States Food and Drug Administration (US-FDA) is leading this trend, worldwide [120].

Of course, all this is driven by the growing capability of simulation technologies to accurately simulate complex physiological processes, such as the progression of a disease, the effect of interventions on such progression, and in some cases the manifestation of side effects and complications due to these interventions. This relies on significant pre-competitive research investments done in the last 10 years in the area of physiological modelling [120].

The general approach to establish the credibility of *in silico* clinical trials revolves around the assumption that in vivo studies, whether on animals or on humans are the most reliable source of information, and any *in silico* approach should be validated against them. Thus, in the clinical assessment of subject-specific models, a group of patients is examined to collect quantitative information required to initialize the model, which is then used to predict one or more outcome biomarkers for each patient. The same outcome biomarkers are then observed experimentally, whether using an invasive technique or after enough time to make the direct experimental observation possible [120].

All this is based on the assumption that in vivo clinical trials work fine, and the motivation for replacing them is related to the risk, duration or cost that the trial involves, but not to their ability to provide a reliable answer on the safety and/or efficacy of a new biomedical product [120].

In the field of diabetes research, *in silico* experiments are of enormous value to accelerating technology development since it is often not possible, appropriate, convenient, or desirable to perform an experiment on human subjects because it cannot be done at all, or it is too difficult, too dangerous, or unethical. In such cases, simulation offers an alternative way of experimenting *in silico* with the system [121]. Several simulation models have been published since the 1960s, mostly in biomedical engineering journals ([122]-[128]) but their impact in the field has been virtually zero. The reason is that all of these models were average models, and, as a result, their capabilities were generally limited to predicting a population average that would be observed during a clinical trial. However, given the large inter-individual variability, an average model approach cannot describe realistically the variety of individual responses to diabetes treatment. Thus, to enable realistic *in silico* experimentation, it is necessary to have a diabetes simulator equipped with a cohort of *in silico* subjects that spans sufficiently well the observed inter-individual variability of key metabolic parameters in the population of people with type 1 (T1D) and type 2 (T2D) diabetes.

In particular, in T1D, *in silico* experiments have been of enormous value to accelerate technology development, e.g. subcutaneous glucose sensors, novel insulin molecules and the artificial pancreas, thanks to the availability of the U.S. Food and Drug Administration (FDA) accepted UVA/Padova T1D simulator

[128][130][131], which allows a time- and cost-effective alternative to preclinical studies, (e.g. [132]).

8.1 The FDA Accepted UVA/Padova T1D Simulator

The FDA-accepted University of Virginia (UVA)/Padova T1D simulator has had a serendipity beginning. In 2006, as part of a NIH program project studying the effects of two-year administration of youth pills in elderly men and women, physiological performance, body composition, and bone density were measured in 204 individuals without diabetes [40][120]. These subjects underwent a triple-tracer meal protocol (see section 7.2.2) which provided, in addition to plasma glucose and insulin concentrations, model-independent estimates of key fluxes of the glucose system, including the rate of appearance in plasma of ingested carbohydrates, endogenous glucose production, glucose utilization, and insulin secretion [40][121]. This rich flux and concentration portrait was key to develop a large-scale glucose–insulin model, which was impossible to build from only plasma glucose and insulin concentrations. A model including 18 differential equations with 42 parameters, 33 of which were free and 9 were derived from steady state constraints, was identified in each individual using a Bayesian forcing function strategy [133]. From the model parameter estimates of the 204 subjects participating in this study, the inter-individual variability was described in a population without diabetes. From there, using the joint multivariate probability distribution of the model parameters, any number of virtual subjects could be generated by random sampling, thereby producing a virtual population. Simultaneously with the events above, and thanks to the advent of minimally invasive subcutaneous (sc) continuous glucose monitoring (CGM), increasing academic, industrial, and political effort has been focused on the development of a sc–sc closed-loop control system for diabetes, which is known as the artificial pancreas (AP). Generally, the AP uses a CGM coupled with a sc insulin infusion pump and a control algorithm directing insulin dosing in real time.

In September 2006, the Juvenile Diabetes Research Foundation (JDRF), initiated the Artificial Pancreas (AP) Project and funded a consortium of university centres in the United States and Europe to carry closed-loop control research. At the time, the regulatory agencies mandated demonstration of the safety and feasibility of AP systems in animals, for example, dogs or pigs, before any testing could begin in humans. This approach is well illustrated by two papers showing the use of the Medtronic AP system first in 8 dogs [134] and then, later, in 10 people with T1D [135]. However, it also became evident that animal studies were slow, not powered for variability and costly, and that a simulator of T1D would allow a cost-effective pre-clinical testing of AP control strategies by providing direction for subsequent clinical research and ruling out ineffective control scenarios. We argued that a reliable large-scale simulator would account better for inter-subject variability than small-size animal trials and would allow for fast and extensive testing of the limits and robustness of AP control algorithms.

We therefore set to build a simulation environment based on the data and the expertise accumulated at the University of Padova and the University of Virginia, two groups that were already collaborating on several aspects of diabetes technology. A first necessary modification of the existing model [133] was the substitution of endogenous insulin secretion subsystem with an exogenous sc insulin delivery, that is, an insulin pump. This required describing insulin absorption with a two-compartment model approximating non-monomeric and monomeric insulin fractions in the sc space. Given the absence in 2006 of tracer studies in T1D similar to those described above for healthy subjects, a more difficult task was the description of inter-person variability.

In order to obtain the joint model parameter distributions in T1D, we introduced certain clinically relevant modifications to the models developed in health. The resulting T1D simulation model included 13 differential equations and 35 parameters, 26 of which were free and 9 were derived from steady-state constraints. Once the T1D model was built, its validity was tested using number of T1D data sets including adults, adolescents, and children. Now the UVA/Padova simulator is equipped with 300 virtual subjects: 100 adults, 100 adolescents, and 100 children, spanning the variability of the T1D population observed in vivo. In addition, the simulator is equipped with models of CGM and insulin pumps. With this technology, any meal and insulin delivery scenario can be tested efficiently *in silico*, prior to its clinical application [128]. After extensive testing, in January 2008, this simulator was accepted by the US FDA as a substitute to animal trials for the pre-clinical testing of control strategies in AP studies and has been adopted by the JDRF AP Consortium as a primary test bed for new closed-loop control algorithms. The simulator was immediately put to its intended use with the *in silico* testing of a new model predictive control (MPC) algorithm, and in April 2008, an investigational device exemption (IDE) was granted by the FDA for a closed-loop control clinical trial. This IDE was issued solely on the basis of *in silico* testing of the safety and efficacy of AP control algorithm, an event that set a precedent for future clinical studies [132]. In brief, to test the validity of the computer simulation environment independently from the data used for its development, a number of experiments were conducted, aiming to assess the model capability to reflect the variety of clinical situations as closely as possible. These experiments included the following:

1. Reproducing the distribution of insulin correction factors in the T1D population of children and adults, which tests that the variability in the action of insulin administered by control algorithms will reflect the variability in observed insulin action;

2. Reproducing glucose traces in children with T1D observed in clinical trials performed by the Diabetes Research in Children Network (DirecNet) consortium;

3. Reproducing glucose traces of induced moderate hypoglycemia observed in adults in clinical trials at the UVA, which provides comprehensive evaluation of control algorithms during hypoglycemia.

Thus, the following paradigm has emerged: (1) *in silico* modeling could produce credible preclinical results that could substitute certain animal trials and (2) *in silico*

testing yields these results in a fraction of the time and the cost required for animal trials. This was a paradigm change in the field of T1D research: for the first time, a computer model has been accepted by a regulatory agency as a substitute of animal trials in the testing of insulin treatments. Since its introduction, this simulator enabled an important acceleration of AP studies, with a number of regulatory approvals obtained using *in silico* testing. However, one needs to emphasize that good *in silico* performance of a control algorithm does not guarantee in vivo performance; it only helps to test the stability of the algorithm in extreme situations and to rule out inefficient scenarios. Thus, computer simulation is only a prerequisite to, but not a substitute for, clinical trials.

Later, new data became available on hypoglycemia and counter-regulation, which allowed an update of the *in silico* model in 2014 [130]. This new version has been proven to be valid on single-meal scenarios showing that the simulator was capable of well describing glucose variability observed in 24 type 1 diabetes subjects who received dinner and breakfast in two occasions (open- and closed-loop), for a total of 96 post-prandial glucose profiles [136]. The simulator domain of validity was then extended by the introduction of diurnal patterns of insulin sensitivity based on data in 19 T1D subjects who underwent a triple-tracer study [64][137](see paragraph 3.4). This has allowed the incorporation of a circadian time-varying insulin sensitivity into the simulator, thus making this technology suitable for running one-day multiple-meal scenarios and enabling a more robust design of AP control algorithms [131].

Finally, another validation of the simulator was done by comparing its predictions to data of 47 T1D subjects from 6 clinical centres, who underwent three randomized 23-h admissions, one open- and two closed-loop. The protocol approximated real life with breakfast, lunch and dinner and collected 141 daily traces of glucose and insulin concentrations. We used Maximum a Posteriori Bayesian approach, which exploited both the information provided by the data and the a priori knowledge on model parameters represented by the joint parameter distribution of the simulator. Plasma insulin concentration was used as model-forcing function, that is, assumed to be known without error. The identification of the simulator on a specific person provided an *in silico* "clone" of this person; thus, the possibility emerged to clone a large number of T1D individuals and to move from single- meal to breakfast/lunch/dinner scenario, thus accounting for intra-subject variation in glucose absorption and insulin sensitivity [138]. This new feature, together with a model of dawn phenomenon data has been incorporated in a new version of T1D simulator [131]. This version also includes a more realistic model of sc insulin delivery, models of both intra-dermal and inhaled insulin pharmacokinetics, and new models of error affecting continuous glucose monitoring and self-monitoring of blood glucose devices (Figures 11 and 12) .

Since 2012, the AP studies successfully moved to outpatient free-living environment and became longer, with durations of up to several weeks/months [139][140][141][142][143][144]. These trials are collecting large amounts of data, typically including closed-loop control and an open-loop mode as a comparator.

The UVA/Padova T1D simulator has been used in a variety of contexts by several research groups in academia, by companies active in the field of diabetes pharma

and technology and has led to more than one thousand publications in peer reviewed journals. Three major application areas which emerged recently are:

i) new generation of closed-loop control algorithms. In particular, the simulator allows to assess individualization strategies, that is, methods for tuning the control algorithm to a specific person [145] and, thus making the AP to be adaptive, that is, learning from the behaviour in time of a specific person [146] [147][148][149][150].

ii) testing safety and efficacy of a Do-It-Yourself algorithm, specifically an AndroidAPS implementation of the OpenAPS algorithm [151].

iii) detection of insulin pump malfunctioning to improve safety of an artificial pancreas [152].

iv) testing of new insulin molecules (Figure 13), e.g. pramlintide [153][154], inhaled technosphere insulin [155], fast [156] and long acting insulin analogues [157][158].

v) testing glucose sensors. Of particular relevance was the use of the simulator to address an important topic of investigation for the diabetes community and regulatory agencies: is CGM safe and effective enough to substitute SMBG in diabetes management? *In silico* clinical trials were performed with a patient decision-making model ([159]) able to recreate real-life conditions (e.g., 100 adults and 100 pediatric patients, 3 meals per day with variability in time and amount, and meal bolus behaviour) (Figure 14).

The simulations helped the outcome of an FDA panel meeting [160][161].

8.2 The Padova T2D Simulator

Among the almost 500 million people in the world having diabetes, only 10-15% has T1D. The vast majority are subjects with type 2 diabetes (T2D). These patients are often treated with medications to control their blood glucose levels: some of these medications are orally administered (e.g., biguanides, sulfonylureas, Dipeptidyl Peptidase 4 inhibitors) [162] some others are given by injection (e.g., insulin, amylin analogues, Glucagon-Like Peptide-1 receptor agonists) [163]. Testing new treatments or combination of medications is time consuming and expensive. Therefore, a simulator to perform ISCT in T2D would be highly desirable. Very recently, we have developed a single meal T2D simulator [164] using a data base of 51 T2D subjects [36][60][62][165], studied with the triple-tracer meal technique [40] and following the successful modeling methodology employed in the development of the T1D simulator.

Figure 15.A reports the mean ± standard deviation (SD) of measured plasma glucose, insulin and C-peptide concentrations, Ra_{meal}, EGP and U in T2D subjects. The model scheme describing the glucose-insulin interaction in T2D subjects is shown in figure 15.B (we refer to [164] for the complete list of model equations and the meaning of the model parameters).

Briefly, the model derives from that proposed by Dalla Man and colleagues in 2007 [133]. Like the original model, this one describes the glucose transit through the gastro-intestinal tract, the action of insulin on glucose utilization and endogenous production, and the control of glucose on insulin secretion. The glucose subsystem is described by a two-compartment model [133]: insulin-independent utilization occurs in the first compartment, representing plasma and rapidly equilibrating tissues, while insulin-dependent utilization occurs in a remote compartment, representing peripheral tissues. At variance with [133], a three-compartment model is used to describe insulin kinetics in the liver (I_l), in the plasma (I_p), and in extravascular space (I_{ev}) [166][167]. A two-compartment model is also added to describe C-peptide kinetics [23][25].

Metabolic fluxes accounted in the model are EGP, Ra_{meal}, glucose utilization (U), β-cell insulin secretion rate (ISR), and hepatic insulin extraction (HE). EGP suppression is assumed to be linearly dependent on plasma glucose, liver insulin, and a delayed plasma insulin signal [88]; one of the key model parameters is hepatic insulin sensitivity (k_{p3}), which quantifies insulin control on EGP suppression. Ra_{meal} is described with a three compartment model, two representing the stomach (solid and triturated compartments), and one the gut [168]. Glucose utilization, U, is made up of two components: insulin-independent utilization (Uii) in the brain and erythrocytes is assumed constant, while insulin-dependent utilization (U_{id}) in muscle and adipose tissues depends nonlinearly (Michaelis–Menten) from glucose in the tissues [169]; one of the key model parameters is disposal insulin sensitivity (V_{mx}). The model also assumes that, when glucose decreases below its basal value, a paradoxical increase in insulin sensitivity occurs, as previously described [130]. ISR is assumed to be made of a basal, a dynamic and a static component, and modeled as in [48], HE is assumed to be linearly related to plasma glucose concentration as in [167].

The availability of the glucose fluxes in addition to plasma glucose, insulin and C-peptide concentrations, allowed identifying the model by using a system decomposition and forcing function strategy, paralleling what was done in [133]. The parameter estimates, obtained from model identification in the 51 T2D subjects, were used to build up the joint parameter distribution, which allowed to generate a T2D *in silico* population.

The model well predicted glucose, insulin, C-peptide, EGP, Ra_{meal} and U data of T2D subjects and the distributions of some key parameters in T2D vs healthy subjects (H) are reported in [164].

A population of 100 *in silico* T2D subjects was generated. Simulated plasma glucose, insulin and C-peptide are compared with T2D data [164]. Results show a good agreement between simulations and data both in terms of population median and variability.

An interesting peculiarity of the simulator, besides well covering the average dynamics, lies in the possibility to evaluate the efficacy of a given treatment in rare, but not so rare, subjects, as discussed in a case study in [164].

This new T2D simulator has the potential to accelerate the research needed to put on the market new antidiabetic drugs. By allowing the evaluation of many treatment scenarios in a cost-effective way.

The availability of 100 virtual subjects is important, since it allows running *in silico* large-scale trials, as usually occurs in phase II clinical trials. In addition, since virtual subjects can undergo the identical experimental scenario several times, one can implement an ideal crossover design, where physiological intra-subject variability is minimized (and controlled by the investigator).

Furthermore, the possibility to virtually recruit a subset of subjects with common characteristics, as shown in the case study of [164] permits to extensively study situations characterized by extreme parameter vectors, sampled from the distribution tails. This could possibly be used for optimizing diabetes therapy also in such rare pathological conditions.

The domain of validity of the simulator is currently the single meal scenario. This might be a limitation for testing treatments that might have a different effect depending on time of administration. For example, long-acting insulin analogues might lead to a different glucose profile depending on morning or evening dosing, as already observed in T1D [170]. A future model refinement will include the description of intra-/inter-day variability of key model parameters, similarly to what has been recently done in H and T1D [63][64], thus improving the simulator reliability on long-term scenarios. In this regard, an ongoing study in T2D will provide important insights on intra- and inter-day variability of insulin sensitivity and beta-cell function [171].

CONCLUSIONS

In this paper we have accompanied the reader to our model-based understanding of the glucose system. We have started with a concise historical background to put our story in a proper perspective. Focus has been on *minimal models* and *maximal models*.

Minimal models provide parametric portraits of the glucose-insulin system from a physiological test, either an MTT or and OGTT. In some sense, minimal models allow to implement Galileo Galilei's statement while teaching at our University in 1592-1610 "...measure what is measurable and make measurable what is not...".The key role of tracers to arrive at a more detailed whole-body picture of insulin action by segregating disposal and liver insulin sensitivity has been discussed. Powerful multi-tracer techniques, i.e. the multiple tracer dilution and the positron emission tomography, which allow to arrive at a more intimate picture insulin action on skeletal muscle has been emphasized. Finally, multi-scale modeling aiming to effectively capture biological interdependencies and interactions among multiple scales has been discussed for insulin secretion by relation whole-body indices to cellular secretory parameters.

Maximal models allow to perform *in silico* studies in life sciences and clinical trials, following their successful but easier use in physical and engineering sciences. Tracers have also allowed to move from a parametric to a flux portrait, enabling the quantitative assessment of postprandial glucose metabolism, and *de facto* allowing to put large scale simulation of Type 1 and Type 2 diabetes on solid data-bases. The

FDA accepted UVA/Padova Type 1 simulator was an unprecedented event in the biological modeling community and proved to be a very useful tool to safely and effectively test *in silico* artificial pancreas control algorithm, glucose sensors for non-adjunctive use and new insulin molecules.

ACKNOWLEGMENTS

REFERENCES

[1]   Cobelli C, Dalla Man C, Sparacino G, Magni L, De Nicolao G, and Kovatchev BP. Diabetes: Models, Signals, and Control. IEEE Reviews in Biomedical Engineering, 2: 54-96, 2009.

[2]   Cobelli C, Dalla Man C, Pedersen MG, Bertoldo A, Toffolo G. Advancing our understanding of the glucose system via modeling: a perspective. IEEE Trans Biomed Eng. 2014 May;61(5):1577-92.

[3]   Schoenheimer R. The Dynamic State of Body Constituents, Harvard University Press, Cambridge, MA. 1942.

[4]   Bier D.M, Leake R.D, Haymond M.W, Arnold K.J, Gruenke L.D, Sperling M.A, Kipnis D.M. Measurement of "true" glucose production rates in infancy and childhood with 6,6-dideuteroglucose. Diabetes. 26(11):1016-23, 1977.

[5]   Sheppard CW. The theory of the study of transfer within a multi-compartment system using isotopic tracers. J. Appl.Physics 19:70-76, 1948.

[6]   Sheppard CW. Basic Principles of the Traçer Method. Wiley, New York, NY, 1962.

[7]   Berman M,.Shahn E, Weiss ME. The routine fitting of kinetic data to models - a mathematical formalism for digital computers. Biophs. J. 2: 275-287, 1962.

[8]   Yalow R.S, Berson SA. Assay of plasma insulin in human subjects by immunological methods. Nature 184, 1648-1649,1959.

[9]   Berman M, Schoenfeld R. Invariants in experimental data on linear kinetics and the formulation of models. J. Appl. Phys. 27:1361-1370, 1956.

[10]   Jacquez JA. Compartmental Analysis in Biology and Medicine. Elsevier, Amsterdam, 1972.

[11]   Cobelli C, DiStefano JJ. III. Parameter and structural identifiability concepts and ambiguities: a critical review and analysis. Am. J. Physiol. 239: R7-R24, 1980.

[12] Landaw EM, DiStefano JJ. III. Multiexponential, multicompartmental, and noncompartmental modeling. Data analysis and statistical considerations. Am. J. Physiol. 246: R665-R667, 1984.

[13] Cobelli C, Carson E.R, Finkelstein L, Leaning MS. The validation of simple and complex models in physiology and medicine. Am. J. Physiol. 246: R259-R266, 1984.

[14] Carson E.R, Cobelli C, Finkelstein L. The Mathematical Modeling of Endocrine-Metabolic Systems. Model Formulation, Identification and Validation. Wiley, New York, 1983.

[15] Carson E. R, and Cobelli C, Modelling Methodology for Physiology and Medicine. San Diego, USA: Academic Press, 2000.

[16] Cobelli C. and Carson E. R, Introduction to Modelling in Physiology and Medicine. 2nd Edition Academic Press, San Diego, 2019.

[17] Steele R, Bjerknes C, Rathgeb I, Altszuler N. Glucose uptake and production during the oral glucose tolerance test. Diabetes 1968;17:415–421.

[18] Norwich KH. Measuring rates of appearance in systems which are not in steady state. Can J Physiol Pharmacol 1973;51:91–101.

[19] Radziuk J. An integral equation approach to measuring turnover in nonsteady compartmental and distributed systems. Bull Math Biol 1976;38: 679–693.

[20] Cobelli C, Mari A, Ferrannini E. Non-steady state: error analysis of Steele's model and developments for glucose kinetics. Am J Physiol 1987;252:E679–E689.

[21] Cobelli C, Toffolo G, and Foster D, Tracer-to-tracee ratio for analysis of stable isotope tracer data: link with radio-active kinetic formalism. Am. J. Physiol, vol. 262, no. 6, pp. E968-E975, 199.

[22] Turner R.C, Grayburn G. A, Newman G. B, and Nabarro JDN. Measurement of the insulin delivery rate in man. J. Clin.. Endocrinol. Metab, vol. 33, no. 2, 279-286, 1971.

[23] Eaton R. P, Allen R. C, Schade DS, Erickson KM, and Standefer J. Prehepatic insulin production in man: kinetic analysis using peripheral connecting peptide behavior. J. Clin. Endocrinol. Metab, vol. 51, no. 3, pp. 520-528, 1980.

[24] Polonsky K. S, Given B. D, Pugh W, Licinio-Paixao J, Thompson J. E, Karrison T. and Rubenstein A. H. Calculation of the systemic delivery rate of insulin in normal man. J. Clin. Endocrinol. Metab, vol. 63, no. 1, pp. 113-118, 1986.

[25] Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels: Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes. 1992;41(3):368-377. doi:10.2337/diabetes.41.3.368.

[26] Bolie V. W. Coefficients of normal blood glucose regulation. J. Appl. Physiol, vol. 16, no. 5, pp. 783-788, 1961.

[27] Ackerman E, Rosevear JW, and McGuckin WF. A mathematical model of the glucose tolerance test. Phys. Med. Biol, vol. 9, no. 2, pp. 203-213, 1964.

[28] Insel P. A, Liljenquist JE, Tobin JD, Sherwin RS, Walkins P, Andres R, and Berman M. Insulin control of glucose metabolism in man. A new kinetic analysis. J. Clin. Invest, vol. 55, no. 5, pp. 1057-1066, 1975.

[29] Sherwin RS, Kramer KJ, Tobin J. D, Insel PA, Liljenquist JE, Berman M and Andres R A model of the kinetics of insulin in man. J. Clin. Invest, vol. 53, no. 5, pp. 1481-1492, 1974.

[30] Bergman RN, Ider YZ, Bowden CR, Cobelli C. Quantitative estimation of insulin sensitivity. Am J Physiol Endocrinol Metab Gastrointest Physiol 236: E667–E677, 1979.

[31] Licko V and Silvers A. Open-loop glucose-insulin control with threshold secretory mechanism: Analysis of intravenous glucose tolerance tests in man. Math Biosci, vol. 27, no. 3-4, pp. 319–332, 1975.

[32] Grodsky GM. A threshold distribution hypothesis for packet storage of insulin and its mathematical modeling. J. Clin. Invest, vol. 51, pp. 2047–2059, 1972.

[33] Toffolo G, De Grandi F, Cobelli C. Estimation of beta-cell sensitivity from intravenous glucose tolerance test C-peptide data. Knowledge of the kinetics avoids errors in modeling the secretion. Diabetes 44:845-54, 1995.

[34] Bergman RN, Phillips LS, Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and Beta-cell sensitivity from the response to intravenous glucose. J Clin Invest 68: 1456–1467, 1981.

[35] Cobelli C, Dalla Man C, Toffolo G, Basu R, Vella A, Rizza R. The oral minimal model method. Diabetes. 2014 Apr;63(4):1203-13.

[36] Dalla Man C, Bock G, Giesler PD, Serra DB, Saylan Ligueros M, Foley JE, Camilleri M, Toffolo G, Cobelli C, Rizza RA, Vella A. Dipeptidyl peptidase-4 inhibition by vidagliptin and the effect of insulin secretion and action in response to meal ingestion in type 2 diabetes. Diabetes Care 32:14-8, 2009.

[37] Sathananthan A, Dalla Man C, Zinsmeister AR, Camilleri M, Rodeheffer RJ, Toffolo G, Cobelli C, Rizza RA, Vella A. A concerted decline in insulin secretion and action occurs across the spectrum of fasting and postchallenge glucose concentrations. Clin Endocrinol (Oxf) 76: 212-9, 2012.

[38] Caumo A, Vicini P, Zachwieja J.J, Avogaro A, Yarasheski K, Bier DM, Cobelli C.: Undermodeling affects minimal model indexes: insights from a two-compartment model. Am. J. Physiol. 276: E1171-1193, 1999.

[39] Toffolo G, Campioni M, Basu R, Rizza RA, Cobelli C. A minimal model of insulin secretion and kinetics to assess hepatic insulin extraction. Am J Physiol Endocrinol Metab. 290: E169-E176, 2006.

[40] Basu R, Dalla Man C, Campioni M, Basu A, Klee G, Toffolo G, Cobelli C, Rizza RA. Effects of age and gender on postprandial glucose metabolism: differences in glucose turnover, insulin secretion, insulin action, and hepatic insulin extraction. Diabetes 55: 2001–2014, 2006.

[41] Dalla Man C, Campioni M, Polonsky KS, Basu R, Rizza RA, Toffolo G, Cobelli C. Two-hour seven-sample oral glucose tolerance test, and meal protocol: minimal model assessment of beta-cell responsivity and insulin sensitivity in nondiabetic individuals. Diabetes 54: 3265–3273, 2005.

[42] Cobelli C, Caumo A, Omenetto M.: Minimal model S_G overestimation and S_I underestimation: improved accuracy by a Bayesian two-compartment model. Am. J. Physiol. 277: E481-488, 1999.

[43] Dalla Man C, Caumo A, Cobelli C. The oral glucose minimal model: estimation of insulin sensitivity from a meal test. IEEE Trans Biomed Eng 49: 419–429, 2002.

[44] Dalla Man C, Caumo A, Basu R, Rizza R, Toffolo G, Cobelli C. Minimal model estimation of glucose absorption and insulin sensitivity from an oral test: validation with a tracer method. Am J Physiol Endocrinol Metab 287: E637–E643, 2004.

[45] Dalla Man C, Yarasheski KE, Caumo A, Robertson H, Toffolo G, Polonsky KS, Cobelli C. Insulin sensitivity by oral glucose minimal models: validation against clamp. Am J Physiol Endocrinol Metab 289: E954–E959, 2005.

[46] Bock G, Dalla Man C, Campioni C, Chittilapilly E, Basu R, Toffolo G, Cobelli C, Rizza R. Effects of nonglucose nutrients on insulin secretion and action in people with pre-diabetes. Diabetes 56: 1113–1119, 2007.

[47] Cobelli C, Toffolo GM, Dalla Man C, Campioni M, Denti P, Caumo A, Butler P, Rizza RA. Assessment of beta-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests. Am. J. Physiol. Endocrinol. Metab. 293:E1 -15, 2007.

[48] Breda E, Cavaghan MK, Toffolo G, Polonsky KS, Cobelli C. Oral glucose tolerance test minimal model indexes of beta-cell function and insulin sensitivity. Diabetes 50: 150 –158, 2001.

[49] Denti P, Toffolo GM, Cobelli C. The disposition index: from individual to population approach. Am. J. Physiol. Endocrinol. Metab. 303:E576-586, 2012.

[50] Campioni M, Toffolo G, Shuster LT, Service J, Rizza R, Cobelli C. Incretin effect potentiates beta-cell responsivity to glucose as well as to its rate of change: OGTT and matched intravenous study. Am J Physiol Endocrinol Metab 292: E54–E60, 2007.

[51] Dalla Man C, Micheletto F, Sathananthan A, Rizza RA, Vella A, Cobelli C. A model of GLP-1 action on insulin secretion in nondiabetic subjects. Am J Physiol Endocrinol Metab. 298: E1115-21, 2010.

[52] Dalla Man C, Micheletto F, Sathananthan M, Vella A, Cobelli C. Model-Based Quantification of Glucagon-Like Peptide-1-Induced Potentiation of Insulin Secretion in Response to a Mixed Meal Challenge. Diabetes Technol Ther. 2016 Jan;18(1):39-46.

[53] Campioni M, Toffolo G.M, Basu R, Rizza R.A, Cobelli C.: Minimal model assessment of hepatic insulin extraction during an oral test from standard insulin kinetic parameters. Am. J. Physiol. Endocrinol. Metab. 298: E941-8, 2009.

[54] Nair KS, Rizza RA, O'Brein P, Short KR, Nehra A, Vittone JL, Klee GG, Basu A, Basu R, Cobelli C, Toffolo G, Dalla Man C, Tindall DJ, Melton LJ, Smith GE, Khosla S, Jensen MD. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 355: 1647–1659, 2006.

[55] Petersen FK, Dufour S, Feng J, Befroy D, Dzuira J, Dalla Man C, Cobelli C, Shulman G. Increased prevalence of insulin resistance and non-alcoholic fatty liver disease in asian indian men. Proc Natl Acad Sci USA 103: 18273–18277, 2006.

[56] Møller JB, Dalla Man C, Overgaard RV, Ingwersen SH, Tornøe CW, Pedersen M, Tanaka H, Ohsugi M, Ueki K, Lynge J, Vasconcelos NM, Pedersen BK, Kadowaki T, Cobelli C. Ethnic differences in insulin sensitivity, β-cell function, and hepatic extraction between Japanese and Caucasians: a minimal model analysis. J Clin Endocrinol Metab. 2014 Nov;99(11):4273-80

[57] Sunehag A.L, Dalla Man C, Toffolo G, Haymond M.W, Bier D.M, Cobelli C. Beta-Cell function and insulin sensitivity in adolescents from an OGTT. Obesity (Silver Spring) 17:233-9, 2009.

[58] Cali AM, Dalla Man C, Cobelli C, Dziura J, Seyal A, Shaw M, Allen K, Chen S, Caprio S. Primary defects in beta-cell function further exacerbated by worsening of insulin resistance mark the development of impaired glucose tolerance in obese adolescents. Diabetes Care. 32:456-61, 2009.

[59] Chandler-Laney PC, Phadke R.P, Granger WM, Muñoz JA, Dalla Man C, Cobelli C, Ovalle F, Fernández JR, Gower BA. Adiposity and β-cell function: relationships differ with ethnicity and age. Obesity 18:2086-2092, 2010.

[60] Bock G, Dalla Man C, Campioni C, Chittilapilly E, Basu R, Toffolo G, Cobelli C, Rizza R. Pathogenesis of pre-diabetes: mechanisms of fasting and postprandial hyperglycemia in people with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 55: 3536–3549, 2006.

[61] Bock G, Chittilapilly E, Basu R, Toffolo G, Cobelli C, Chandramouli V, Landau B.R, and Rizza R.A. Contribution of hepatic and extrahepatic insulin resistance to the pathogenesis of impaired fasting glucose: role of increased rates of gluconeogenesis. Diabetes 56:1703-1711, 2007.

[62] Basu A, Dalla Man C, Basu R, Toffolo G, Cobelli C, Rizza RA. Effects of Type 2 diabetes on insulin secretion, insulin action, glucose metabolism. Diabetes Care 32:866-72, 2009.

[63] Saad A, Dalla Man C, Nandy DK, Levine JA, Bharucha AE, Rizza RA, Basu R, Carter RE, Cobelli C, Kudva YC, Basu A. Diurnal pattern to insulin secretion and insulin action in healthy individuals. Diabetes 61:2691-700, 2012.

[64] Hinshaw L, Dalla Man C, Nandy DK, Saad A, Bharucha AE, Levine JA, Rizza R.A, Basu R, Carter RE, Cobelli C, Kudva YC, Basu A. Diurnal pattern of insulin action in type 1 diabetes: implications for a closed loop system. Diabetes, 2013.

[65] Hodson K, Dalla Man C, Smith FE, Thelwall PE, Cobelli C, Robson SC, Taylor R.:Mechanism of insulin resistance in normal pregnancy. Horm. Metab. Res 45:567-571, 2013.

[66] Bock G, Dalla Man C, Micheletto F, Basu R, Giesler P.D, Laugen J, Deacon CF, Holst JJ, Toffolo G, Cobelli C, Rizza RA, Vella A. The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting

and postprandial glucose turnover in subjects with impaired fasting glucose. Clinical Endocrinology 73: 189-196, 2010.

[67] Smushkin G, Sathananthan M, Piccinini F, Dalla Man C, Law J.H, Cobelli C, Zinsmeister AR, Rizza RA, Vella A. The effect of a bile Acid sequestrant on glucose metabolism in subjects with type 2 diabetes. Diabetes 62:1094-1101, 2013.

[68] Hodson K, Dalla Man C, Smith FE, Barnes A, McParlin C, Cobelli C, Robson SC, Araújo-Soares V, Taylor R. Liver triacylglycerol content and gestational diabetes: effects of moderate energy restriction. Diabetologia. 2017 Feb;60(2):306-313.

[69] Bynoe K, Unwin N, Taylor C, Murphy MM, Bartholomew L, Greenidge A, Abed M, Jeyaseelan S, Cobelli C, Dalla Man C, Taylor R. Inducing remission of Type 2 diabetes in the Caribbean: findings from a mixed methods feasibility study of a low-calorie liquid diet-based intervention in Barbados. Diabet Med. 2019 Jul 31.

[70] Sathananthan M, Ikramuddin S, Swain JM, Shah M, Piccinini F, Dalla Man C, Cobelli C, Rizza RA, Camilleri M, Vella A. The effect of vagal nerve blockade using electrical impulses on glucose metabolism in nondiabetic subjects. Diabetes Metab Syndr Obes. 2014 Jul 11;7:305-12.

[71] Giannini C, Dalla Man C, Groop L, Cobelli C, Zhao H, Shaw MM, Duran E, Pierpont B, Bale AE, Caprio S, Santoro N. Co-occurrence of Risk Alleles in or Near Genes Modulating Insulin Secretion Predisposes Obese Youth to Prediabetes DIABETES CARE 37; 475- 482, 2014.

[72] Zheng C, Dalla Man C, Cobelli C, Groop L, Zhao H, Bale AE, Shaw M, Duran E, Pierpont B, Caprio S, Santoro N. A common variant in the MTNR1b gene is associated with increased risk of impaired fasting glucose (IFG) in youth with obesity. Obesity (Silver Spring). 2015 May;23(5):1022-9.

[73] Cropano C, Santoro N, Groop L, Dalla Man C, Cobelli C, Galderisi A, Kursawe R, Pierpont B, Goffredo M, Caprio S. The rs7903146 Variant in the TCF7L2 Gene Increases the Risk of Prediabetes/Type 2 Diabetes in Obese Adolescents by Impairing β-Cell Function and Hepatic Insulin Sensitivity. Diabetes Care. 2017 Aug;40(8):1082-1089..

[74] Vasques AC, Pareja JC, Souza JR, Yamanaka A, de Oliveira Mda S, Novaes FS, Chaim ÉA, Piccinini F, Dalla Man C, Cobelli C, Geloneze B. Epicardial and pericardial fat in type 2 diabetes: favourable effects of biliopancreatic diversion. Obes Surg. 2015 Mar;25(3):477-85..

[75] Vasques AC, Pareja JC, da Saúde de Oliveira M, Novaes FS, Lima MM, Chaim ÉA, Piccinini F, Dalla Man C, Cobelli C, Geloneze B. Long-Term Outcomes of Biliopancreatic Diversion on Glycemic Control, Insulin Sensitivity and Beta Cell Function. Obes Surg. 2016 Nov;26(11):2572-2580.

[76] Purnell JQ, Johnson GS, Wahed AS, Dalla Man C, Piccinini F, Cobelli C, Prigeon RL, Goodpaster BH, Kelley DE, Staten MA, Foster-Schubert KE, Cummings DE, Flum DR, Courcoulas AP, Havel PJ, Wolfe BM. Prospective evaluation of insulin and incretin dynamics in obese adults with and without

diabetes for 2 years after Roux-en-Y gastric bypass. Diabetologia. 2018 May;61(5):1142-1154.

[77] Shah M, Laurenti MC, Dalla Man C, Ma J, Cobelli C, Rizza RA, Vella A. Contribution of endogenous glucagon-like peptide-1 to changes in glucose metabolism and islet function in people with type 2 diabetes four weeks after Roux-en-Y gastric bypass (RYGB). Metabolism. 2019 Apr;93:10-17.

[78] Sharma A, Laurenti MC, Dalla Man C, Varghese RT, Cobelli C, Rizza RA, Matveyenko A, Vella A. Glucose metabolism during rotational shift-work in healthcare workers. Diabetologia. 2017 Aug;60(8):1483-1490.

[79] Qian J, Dalla Man C, Morris CJ, Cobelli C, Scheer FA. Differential effects of the circadian system and circadian misalignment on insulin sensitivity and insulin secretion in humans. Diabetes Obes Metab. 2018 Oct;20(10):2481-2485.

[80] Brede S, Fehr S, Dalla-Man C, Cobelli C, Lehnert H, Hallschmid M, Klement J. Intranasal oxytocin fails to acutely improve glucose metabolism in obese men. Diabetes Obes Metab. 2019 Feb;21(2):424-428.

[81] Visentin R, Schiavon M, Göbel B, Riz M, Cobelli C, Klabunde T, Dalla Man C. Dual glucagon-like peptide-1 receptor/glucagon receptor agonist SAR425899 improves beta-cell function in type 2 diabetes. Diabetes Obes Metab. 2020 Apr;22(4):640-647.

[82] Carson E and Cobelli C, Modeling Methodology for Physiology and Medicine. Second Edition. Elsevier 2014.

[83] Dalla Man C, Caumo A, Basu R, Rizza R, Toffolo G, Cobelli C. Measurement of selective effect of insulin on glucose disposal from labeled glucose oral test minimal model. Am J Physiol Endocrinol Metab.289:E909-14, 2005.

[84] Avogaro A, Vicini P, Valerio A, Caumo A, Cobelli C. The hot but not the cold minimal model allows precise assessment of insulin sensitivity in NIDDM subjects. Am J Physiol. 1996 Mar;270(3 Pt 1):E532-40.

[85] Saad MF, Anderson R, Laws A, Watanabe R, Kades W, Sands YCR, Pei D, Savage P, and Bergman RN. A comparison between the minimal model and the glucose clamp in the assessment of insulin sensitivity across the spectrum of glucose tolerance. Diabetes 1994; 43: 1114–21.

[86] Cobelli C, Pacini G, Toffolo G, and Sacca L. Estimation of insulin sensitivity and glucose clearance from minimal model: new insights from labelled IVGTT. Am. J. Physiol.: Endocrinol. Metab. 1986; 250: 591–8

[87] Basu R, Di Camillo B, Toffolo G, Basu A, Shah P, Vella A, Rizza R, Cobelli C. Use of a novel triple tracer approach to assess postprandial glucose metabolism. Am. J. Physiol.: Endocrinol. Metab. 2003.;284(1):55-69

[88] Dalla Man C, Toffolo G, Basu R, Rizza RA, Cobelli C. Use of labelled oral minimal model to measure hepatic insulin sensitivity. Am. J. Physiol.: Endocrinol. Metab. 2008: 295(5):1152-9.

[89] Dalla Man C, Piccinini F, Basu R, Basu A, Rizza RA, Cobelli C. Modelling hepatic insulin sensitivity during a meal: validation against the euglycemic hyperinsulinemic clamp. Am. J. Physiol.: Endocrinol. Metab. 2013;304(8):819-25.

[90] Visentin R, Dalla Man C, Basu R, Basu A, Rizza RA, Cobelli C. Hepatic insulin sensitivity in healthy and prediabetic subjects: from a dual- to a single-tracer oral minimal model. Am J Physiol Endocrinol Metab. 2015 Jul 15;309(2):E161-7.

[91] Kuikka J, Levin M, Bassingthwaighte J.B.. Multiple tracer dilution estimates of D- and 2-deoxy-D-glucose uptake by the heart. Am. J. Physiol. 250:H29-H42, 1986.

[92] Bassingthwaighte JB, Goresky CA. Modeling in the analysis of solute and water exchange in the microvasculature. In Handbook of Physiology – The Cardiovascular System. Microcirculation. Bethesda, MD: American Society of Physiology, 1984.

[93] Jacquez J.A. Compartmental Analysis in Biology and Medicine, 2nd ed. Ann Arbor, MI: University of Michigan Press, 1985.

[94] Cobelli C, Saccomani M.P, Ferrannini E, DeFronzo RA, Gelfand R, Bonadonna RC. A compartmental model to quantitate in vivo glucose transport in the human forearm. Am. J. Physiol. 257: E943-E958, 1989.

[95] Bonadonna RC, Saccomani MP, Seely L, Starick Zych K, Ferrannini E, Cobelli C, DeFronzo RA. Glucose transport in human skeletal muscle: the in vivo response to insulin. Diabetes 42:191- 198, 1993.

[96] Saccomani MP, Bonadonna RC, Bier DM, De Fronzo RA. and Cobelli C. A compartmental model to measure the effects of insulin on glucose transport and phosphorylation in human skeletal muscle. A triple tracer study. Am. J. Physiol. 270:E170-E185, 1996.

[97] Bonadonna RC, Del Prato S, Bonora E, Saccomani MP, Gulli G, Natali A, Frascerra S, Pecori N, Ferrannini E, Bier D.M, Cobelli C, De Fronzo R.A. Roles of glucose transport and glucose phosphorylation in muscle insulin resistance of NIDDM. Diabetes 45: 915-925, 1996..

[98] Pendergrass M, Bertoldo A, Bonadonna RC, Nucci G, Mandarino L, Cobelli C, DeFronzo R.A. Muscle glucose transport and phosphorylation in type 2 diabetic, obese nondiabetic, and genetically predisposed individuals, Am J Physiol Endocrinol Metab 292:E92-E100, 2007.

[99] Sokoloff L, Reivich M, Kennedy C, Des-Rosiers M.H, Patlak CS, Pettigrew KD, Sakurada O, Shinohara M.. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J. Neurochem 28:897-916, 1977.

[100] Utriainen T, Mäkimattilla S, Lovisatti S, Bertoldo A, Bonadonna RC, Weintraub S, De Fronzo R, Cobelli C, Yki-Järvinen H. Lumped constant for [14C]deoxy-D-glucose in human skeletal muscle. Diabetologia 41:A187, 1998.

[101] Kelley D.E, Williams K.V, Price J.C. and Goodpaster B. Determination of the lumped constant for [18F]FDG in human skeletal muscle. J. Nucl. Med. 40:1798-1804, 1999.

[102] Bertoldo A, Peltoniemi P, Oikonen V, Knuuti J, Nuutila P, Cobelli C. Kinetic modeling of [(18)F]FDG in skeletal muscle by PET: a four-compartment

five-rate-constant model, Am J Physiol Endocrinol Metab 281:E524-E536, 2001.

[103] Bertoldo A, Pencek RR, Azuma K, Price JC, Kelley C, Cobelli C, Kelley DE. Interactions between delivery, transport, and phosphorylation of glucose in governing uptake into human skeletal muscle, Diabetes 55:3028-3037, 2006.

[104] Pedersen M. G, Corradin A, Toffolo G. M, Cobelli C.A subcellular model of glucose-stimulated pancreatic insulin secretion. Philos Transact A Math Phys Eng Sci, vol. 366, no. 1880, pp. 3525–3543, Oct 2008.

[105] Jonkers FC, Henquin JC.,Measurements of cytoplasmic Ca2+ in islet cell clusters show that glucose rapidly recruits beta-cells and gradually increases the individual cell response. Diabetes, vol. 50, pp. 540–550, 2001.

[106] Heart E, Corkey RF, Wikstrom JD, Shirihai O. S, Corkey BE. Glucose-dependent increase in mitochondrial membrane potential, but not cytoplasmic calcium, correlates with insulin secretion in single islet cells. Am. J. Physiol. Endocrinol. Metab, vol. 290, pp. E143–E148, 2006.

[107] Pedersen MG, Sherman A. Newcomer insulin secretory granules as a highly calcium-sensitive pool. Proc Natl Acad Sci U S A, vol. 106, no. 18, pp. 7432–7436, May 2009.

[108] Pedersen MG, Toffolo GM, Cobelli C. Cellular modeling: insight into oral minimal models of insulin secretion. Am J Physiol Endocrinol Metab, vol. 298, no. 3, pp. E597–E601, Mar 2010.

[109] Pedersen M. G, Dalla Man C, Cobelli C. Multiscale modeling of insulin secretion. IEEE Trans Biomed Eng, vol. 58, no. 10, pp. 3020–3, Oct 2011.

[110] Rizza RA, Toffolo G, Cobelli C. Accurate Measurement of Postprandial Glucose Turnover: Why Is It Difficult and How Can It Be Done (Relatively) Simply?. Diabetes. 2016;65(5):1133-1145.

[111] Steele R, Bjerknes C, Rathgeb I, Altszuler N. Glucose uptake and production during the oral glucose tolerance test. Diabetes 1968;17:415–421.

[112] Finegood DT, Bergman RN, Vranic M. Modeling error and apparent isotope discrimination confound estimation of endogenous glucose production during euglycemic glucose clamps. Diabetes 1988;37:1025–1034

[113] Steele R, Wall JS, De Bodo RC, Altszuler N. Measurement of size and turnover rate of body glucose pool by the isotope dilution method. Am J Physiol 1956;187:15–24.

[114] De Bodo RC, Steele R, Altszuler N, Dunn A, Bishop JS. On the hormonal regulation of carbohydrate metabolism; studies with C14 glucose. Renal Prog Horm Res 1963;19:443–483

[115] Butler PC, Caumo A, Zerman A, O'Brien PC, Cobelli C, Rizza RA. Methods for assessment of the rate of onset and offset of insulin action during nonsteady state in humans. Am J Physiol 1993;264:E548–E560

[116] Allsop JR, Wolfe RR, Burke JF. The realiability of rates of glucose appearance in vivo calculated from constant tracer infusions. Biochem J 1978;172: 407–416.

[117] Toffolo G, Basu R, Dalla Man C, Rizza R, Cobelli C. Assessment of postprandial glucose metabolism: conventional dual- vs. triple-tracer method. Am J Physiol Endocrinol Metab 2006;291:E800–E806.

[118] Toffolo G, Dalla Man C, Cobelli C, Sunehag AL. Glucose fluxes during OGTT in adolescents assessed by a stable isotope triple tracer method. J Pediatr Endocrinol Metab 2008;21:31–45

[119] Basu R, Schiavon M, Petterson XM, et al. A novel natural tracer method to measure complex carbohydrate metabolism. Am J Physiol Endocrinol Metab. 2019;317(3):E483-E493.

[120] Viceconti M, Cobelli C, Haddad T, Himes A, Kovatchev B, Palmer M. *In silico* assessment of biomedical products: The conundrum of rare but not so rare events in two case studies. Proc Inst Mech Eng H. 2017;231(5):455-466.

[121] Visentin R., Schiavon. M., Basu R. , Basu A., Dalla Man C., Cobelli C. "Physiological models for artificial pancreas development" in "The Artificial Pancreas, Current Situation and Future Directions" Academic Press 2019.

[122] Srinivasan, R, Kadish, AH, Sridhar, R. A mathematical model for the control mechanism of free fatty acid-glucose metabolism in normal humans. Comput Biomed Res 1970; 3: 146–165.

[123] Cobelli, C, Federspil, G, Pacini, G. An integrated mathematical model of the dynamics of blood glucose and its hormonal control. Math Biosci 1982; 58: 27–60.

[124] Cobelli, C, Ruggeri, A. Evaluation of portal/peripheral route and of algorithms for insulin delivery in the closed-loop control of glucose in diabetes–a modeling study. IEEE Trans Biomed Eng 1983; 30: 93–103.

[125] Sorensen JT. A physiologic model of glucose metabolism in man and its use to design and assess improved insulin therapies for diabetes. PhD Thesis, Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, 1985.

[126] Salzsieder, E, Albrecht, G, Fischer, U. Kinetic modeling of the glucoregulatory system to improve insulin therapy. IEEE Trans Biomed Eng 1985; 32: 846–855.

[127] Lehmann, ED, Deutsch, T. A physiological model of glucose-insulin interaction in type 1 diabetes mellitus. J Biomed Eng 1992; 14: 235–242.

[128] Andreassen S, Benn JJ, Hovorka R, Olesen KG, Carson ER. A probabilistic approach to glucose prediction and insulin dose adjustment: description of metabolic model and pilot evaluation study. Comput Methods Programs Biomed. 1994 Jan;41(3-4):153-65.

[129] Kovatchev BP, Breton M, Dalla Man C, Cobelli C. *In Silico* Preclinical Trials: A Proof of Concept in Closed-Loop Control of Type 1 Diabetes. J Diabetes Sci Technol. 2009;3(1):44-55.

[130] Dalla Man C, Micheletto F, Lv D, Breton M, Kovatchev B, Cobelli C. The UVA/PADOVA Type 1 Diabetes Simulator: New Features. J Diabetes Sci Technol. 2014;8(1):26-34.

[131] Visentin R, Campos-Náñez E, Schiavon M, et al. The UVA/Padova Type 1 Diabetes Simulator Goes From Single Meal to Single Day. J Diabetes Sci Technol. 2018;12(2):273-281.

[132] Kovatchev, BP, Cobelli, C, Renard, E. Multinational study of subcutaneous model-predictive closed-loop control in type 1 diabetes mellitus: summary of the results. J Diabetes Sci Technol 2010; 4: 1374–1381.

[133] Dalla Man C, Rizza RA, Cobelli C. Meal simulation model of the glucose-insulin system. IEEE Trans Biomed Eng. 2007;54(10):1740-1749.

[134] Panteleon, AE, Loutseiko, M, Steil, GM. Evaluation of the effect of gain on the meal response of an automated closed-loop insulin delivery system. Diabetes 2006; 55: 1995–2000.

[135] Steil, GM, Rebrin, K, Darwin, C. Feasibility of automating insulin delivery for the treatment of type 1 diabetes. Diabetes 2006; 55: 3344–3350.

[136] Visentin, R, Dalla Man, C, Kovatchev, B. The University of Virginia/Padova type 1 diabetes simulator matches the glucose traces of a clinical trial. Diabetes Technol Ther 2014; 16: 428–434.

[137] Visentin, R, Dalla Man, C, Kudva, YC. Circadian variability of insulin sensitivity: physiological input for *in silico* artificial pancreas. Diabetes Technol Ther 2015; 17: 1–7.

[138] Visentin, R, Dalla Man, C, Cobelli, C. One-day Bayesian cloning of type 1 diabetes subjects: toward a single-day UVA/Padova type 1 diabetes simulator. IEEE Trans Biomed Eng 2016; 63: 2416–2424.

[139] Kropff, J, Del Favero, S, Place, J. 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial. Lancet Diabetes Endocrinol 2015; 3: 939–947.

[140] Anderson, SM, Raghinaru, D, Pinsker, JE. Multinational home use of closed-loop control is safe and effective. Diabetes Care 2016; 39: 1143–1150.

[141] Renard, E, Farret, A, Kropff, J. Day-and-night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: results of a single-arm 1-month experience compared with a previously reported feasibility study of evening and night at home. Diabetes Care 2016; 39: 1151–1160.

[142] Thabit H, Tauschmann M, Allen JM, Leelarathna L, Hartnell S, Wilinska ME, Acerini CL, Dellweg S, Benesch C, Heinemann L, Mader JK, Holzer M, Kojzar H, Exall J, Yong J, Pichierri J, Barnard KD, Kollman C, Cheng P, Hindmarsh PC, Campbell FM, Arnolds S, Pieber TR, Evans ML, Dunger DB, Hovorka R. Home Use of an Artificial Beta Cell in Type 1 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2129-2140.

[143] Brown SA, Kovatchev BP, Raghinaru D, Lum JW, Buckingham BA, Kudva YC, Laffel LM, Levy CJ, Pinsker JE, Wadwa RP, Dassau E, Doyle FJ 3rd, Anderson SM, Church MM, Dadlani V, Ekhlaspour L, Forlenza GP, Isganaitis E, Lam DW, Kollman C, Beck RW; iDCL Trial Research Group. Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes. N Engl J Med. 2019 Oct 31;381(18):1707-1717.

[144] Collyns OJ, Meier RA, Betts ZL, Chan DSH, Frampton C, Frewen CM, Hewapathirana NM, Jones SD, Roy A, Grosman B, Kurtz N, Shin J, Vigersky RA, Wheeler BJ, de Bock MI. Improved Glycemic Outcomes With

Medtronic MiniMed Advanced Hybrid Closed-Loop Delivery: Results From a Randomized Crossover Trial Comparing Automated Insulin Delivery With Predictive Low Glucose Suspend in People With Type 1 Diabetes. Diabetes Care. 2021 Apr;44(4):969-975.

[145] Messori, M, Toffanin, C, Del Favero, S. De Nicolao G, Cobelli C, Magni L. Model individualization for artificial pancreas. Comput Methods Programs Biomed. 2019 Apr;171:133-140.

[146] Toffanin, C, Messori, M, Cobelli, C. Automatic adaptation of basal therapy for Type 1 diabetic patients: a Run-to-Run approach. Biomed Signal Process Control 2017; 31: 539–549.

[147] Toffanin C, Visentin R, Messori M, Palma F Di, Magni L, Cobelli C. Toward a Run-to-Run Adaptive Artificial Pancreas: *In Silico* Results. IEEE Trans Biomed Eng. 2018;65(3):479-488.

[148] Shi D, Dassau E, Doyle FJ. Adaptive Zone Model Predictive Control of Artificial Pancreas Based on Glucose- and Velocity-Dependent Control Penalties. IEEE Trans Biomed Eng. 2019;66(4):1045-1054.

[149] Shi D, Dassau E, Doyle FJ 3rd. Multivariate learning framework for long-term adaptation in the artificial pancreas. Bioeng Transl Med. 2018 Nov 12;4(1):61-74.

[150] Messori M, Kropff J, Del Favero S, Place J, Visentin R, Calore R, Toffanin C, Di Palma F, Lanzola G, Farret A, Boscari F, Galasso S, Avogaro A, Keith-Hynes P, Kovatchev BP, Bruttomesso D, Magni L, DeVries H, Renard E, Cobelli C. Individually Adaptive Artificial Pancreas in Subjects with Type 1 Diabetes: A One-Month Proof-of-Concept Trial in Free-Living Conditions. Diabetes Technology & Therapeutics.Oct 2017; 560-571.

[151] Toffanin C, Kozak M, Sumnik Z, Cobelli C, Petruzelkova L. *In Silico* Trials of an Open-Source Android-Based Artificial Pancreas: A New Paradigm to Test Safety and Efficacy of Do-It-Yourself Systems. Diabetes Technol Ther. 2020;22(2):112-120.

[152] Meneghetti L, Susto GA, Del Favero S. Detection of Insulin Pump Malfunctioning to Improve Safety in Artificial Pancreas Using Unsupervised Algorithms. J Diabetes Sci Technol. 2019;13(6):1065-1076.

[153] Micheletto F, Dalla Man C, Kolterman O, Chiquette E, Herrmann K, Schirra J, Kovatchev B, Cobelli C. *In silico* design of optimal ratio for co-administration of pramlintide and insulin in type 1 diabetes. Diabetes Technol Ther. 2013 Oct;15(10):802-9.

[154] Riddle MC, Nahra R, Han J, Castle J, Hanavan K, Hompesch M, Huffman D, Strange P, Öhman P. Control of Postprandial Hyperglycemia in Type 1 Diabetes by 24-Hour Fixed-Dose Coadministration of Pramlintide and Regular Human Insulin: A Randomized, Two-Way Crossover Study. Diabetes Care. 2018 Nov;41(11):2346-2352.

[155] Visentin R, Giegerich C, Jäger R, et al. Improving Efficacy of Inhaled Technosphere Insulin (Afrezza) by Postmeal Dosing: In-silico Clinical Trial with the University of Virginia/Padova Type 1 Diabetes Simulator. Diabetes Technol Ther. 2016;18(9):574-585.

[156] Schiavon M, Dalla Man C, Cobelli C. Modeling Subcutaneous Absorption of Fast-Acting Insulin in Type 1 Diabetes. IEEE Trans Biomed Eng. 2018 Sep;65(9):2079-2086.

[157] Visentin R, Schiavon M, Giegerich C, Klabunde T, Dalla Man C, Cobelli C. Incorporating Long-Acting Insulin Glargine Into the UVA/Padova Type 1 Diabetes Simulator for *In Silico* Testing of MDI Therapies. IEEE Trans Biomed Eng. 2019;66(10):2889-2896.

[158] Schiavon M, Visentin R, Giegerich C, Sieber J, Cobelli C, Dalla Man C, Klabunde T. *In Silico* Head-to-Head Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL in Type 1 Diabetes. Diabetes Technol Ther. 2020 Aug;22(8):553-561.

[159] Vettoretti M, Facchinetti A, Sparacino G, Cobelli C. Type-1 Diabetes Patient Decision Simulator for *In Silico* Testing Safety and Effectiveness of Insulin Treatments. IEEE Trans Biomed Eng. 2018;65(6):1281-1290.

[160] FDA. Brief summary of the clinical chemistry and clinical toxicology devices panel meeting 21 July 2016. Department of Health and Human Services, Food and Drug Administration, http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/ClinicalChemistryandClinicalToxicologyDevicesPanel/UCM513025.pdf

[161] Edelman S V. Regulation Catches Up to Reality. J Diabetes Sci Technol. 2017;11(1):160-164.

[162] Tran L, Zielinski A, Roach AH, et al. Pharmacologic Treatment of Type 2 Diabetes: Oral Medications. Ann Pharmacother. 2015;49(5):540-556.

[163] Tran L, Zielinski A, Roach AH, et al. Pharmacologic Treatment of Type 2 Diabetes: Injectable Medications. Ann Pharmacother. 2015;49(6):700-714.

[164] Visentin R, Cobelli C, Dalla Man C. The Padova Type 2 Diabetes Simulator from Triple-Tracer Single-Meal Studies: *In Silico* Trials Also Possible in Rare but Not-So-Rare Individuals. Diab Technol. Ther. 2020 2020 Dec;22(12):892-903

[165] Vella A, Bock G, Giesler PD, et al. Effects of Dipeptidyl Peptidase-4 Inhibition on Gastrointestinal Function, Meal Appearance, and Glucose Metabolism in Type 2 Diabetes. Diabetes. 2007;56(5):1475 LP - 1480.

[166] Sherwin RS, Kramer KJ, Tobin JD, et al. A model of the kinetics of insulin in man. J Clin Invest. 1974;53(5):1481-1492.

[167] Piccinini F, Dalla Man C, Vella A, Cobelli C. A Model for the Estimation of Hepatic Insulin Extraction after a Meal. IEEE Trans Biomed Eng. 2016;63(9):1925-1932.

[168] Dalla Man C, Camilleri M, Cobelli C. A system model of oral glucose absorption: Validation on gold standard data. IEEE Trans Biomed Eng. 2006;53(12):2472-2478.

[169] Yki-Jarvinen H, Young AA, Lamkin C, Foley JE. Kinetics of glucose disposal in whole body and across the forearm in man. J Clin Invest. 1987;79(6):1713-1719.

[170] Bergenstal RM, Bailey TS, Rodbard D, et al. Comparison of Insulin Glargine 300 Units/mL and 100 Units/mL in Adults With Type 1 Diabetes:

Continuous Glucose Monitoring Profiles and Variability Using Morning or Evening Injections. Diabetes Care. 2017;40(4):554-560.

[171] Yadav Y, Romeres D, Cobelli C, Carter R, Basu A, Dalla Man C, , Basu RDiurnal pattern of meal tolerance and insulin sensitivity in type 2 diabetes. Submitted to 57th EASD 2021.

Figure Legends

Figure 1: Top panel: Mixed meal (left) and OGTT(right) plasma glucose (top), insulin (middle) and C-peptide (bottom) in the same subject. Bottom panel: Partition analysis of the system allows to separately estimate insulin sensitivity, beta-cell responsivity and hepatic extraction without the confounding effect of the two other parameters. Relevant input and output signals of the three models are shown (adapted from [35]).

Figure 2: The oral glucose minimal models which allow to estimate insulin sensitivity (top panel), beta-cell responsivity (middle panel) and hepatic insulin extraction (bottom panel (adapted from [35]).

Figure 3: Schematic diagram to illustrate the importance of expressing beta-cell responsivity in relation to insulin sensitivity is illustrated by using the disposition index metric, i.e. the product of beta-cell responsivity times insulin sensitivity is assumed to be a constant. Left panel: A normal subject (state I) reacts to impaired insulin sensitivity by increasing beta-cell responsivity (state II) while a subject with impaired tolerance does not (state 2). In state II beta-cell responsivity is increased but the disposition index is unchanged, and normal glucose tolerance is retained normal, while in state 2 beta-cell responsivity is normal but not adequate to compensate the decreased insulin sensitivity (state 2), and glucose intolerance is developed. Right panel: Impaired glucose tolerance can arise due to defects of beta-cell responsivity and/or defects of insulin sensitivity. In this hypothetical example, subject X is intolerant due to her/his poor beta-beta-cell function, while subject Y has poor insulin sensitivity. The ability to dissect the underlying physiological defects (insulin sensitivity or beta-cell responsivity) allows to optimize medical treatments (adapted from [35]).

Figure 4: The labeled oral minimal model which allows to estimate disposal insulin sensitivity (adapted from [35]).

Figure 5: Skeletal muscle major glucose processes: diffusion to/from the intersitium, active transport in and out of the cell, and phosphorylation/metabolism.

Figure 6: The 5k model of $[^{18}F]FDG$ in skeletal muscle: C_p is $[^{18}F]FDG$ plasma arterial concentration, C_c extracellular concentration of $[^{18}F]FDG$ normalized to tissue volume, C_e $[^{18}F]FDG$ tissue concentration, Cm $[^{18}F]FDG - 6 - P$ tissue concentration, C total ^{18}F activity concentration in the ROI, K_1 [ml/ml/min] and k_2 [min^{-1}] the exchange between plasma and extracellular space, k_3 [min^{-1}] and k_4 [min^{-1}] transport in and out of cell, k_5 [min^{-1}] phosphorylation.

Figure 7: The three PET tracer protocol to study glucose diffusion through capillary membrane, active transport into the cells and metabolism.

Figure 8: Left panel: Grodsky's [32] model with a large reserve pool and a small labile pool of insulin packets with different thresholds. Right panel: The model [104] with a pool of docked insulin granules (D), a readily releasable pool (RRP)

and a pool of fused granules (F) releasing insulin. The model assumes that beta-cells have different activation threshold with respect to the glucose concentration (G) by distinguishing between RRP granules in active cells (denoted H(G), filled circles) and in silent cells (open circles) (adapted from [2] and [104]).

Figure 9: Scheme of the dual (left) and the triple tracer (right panel) protocol. In the dual tracer protocol the first tracer is mixed with the meal and the second one is infused intravenously with a constant rate. In the triple tracer protocol the first tracer is mixed with the meal, the second one is infused intravenously trying to mimic the expected pattern of EGP and the third one is infused intravenously trying to mimic the expected pattern of Ra_{meal}.

Figure 10: TTR_{exo} (in dpm/μmol) (upper) and TTR_{end} (in dpm/μmol) (lower panel) used in the triple tracer methods in 8 healthy subjects. TTR are in dpm/μmol since in this study the i.v. infused tracer is radioactive [117]**Errore. L'origine riferimento non è stata trovata.**. Vertical bars represent standard error (adapted from [117]).

Figure 11: Scheme of latest version of the UVa/Padova T1D simulator, incorporating time-varying parameters describing intraday variability of insulin sensitivity and dawn phenomenon. The simulator also includes various insulin delivery routes (subcutaneous fast-acting insulin, intradermal and inhaled insulins) and glucose monitoring devices (both CGM and SMBG) (adapted from [131]).

Figure 12: Simulated plasma glucose (upper) and insulin (lower panels) in the 100 *in silico* adults (left), adolescents (middle), and children (right panels) available in the UVa/Padova T1D simulator. Subjects underwent a 24-hour scenario with three identical meals (60 g of CHO) at 7:00 am, 1:00 pm, 7:00 pm, respectively, and received optimal subcutaneous insulin basal and bolus (adapted from [131]).

Figure 13: The use of the UVa/Padova T1D simulator for testing new molecules: once the PK-PD of the molecule under investigation is incorporated in the simulator, simulations can be run predicting clinical outcomes, e.g. optimal dosing, safety and efficacy.

Figure 14: Block-scheme representing the T1D patient decision simulator. Arrows entering each block are inputs, while arrows exiting are causally-related outputs. The input of the simulator is the sequence of meals, while the output is the BG concentration profile. The simulator includes parameters describing the patient's physiology and therapy. The picture reports representative time courses for meals in input and BG in output for a simple scenario in which the patient takes 50 g for breakfast at 07:00 am (adapted from [159]).

Figure 15: Upper panel: average (filled circle) $\pm$ standard deviation (SD, shaded area) plasma glucose, insulin and C-peptide concentration and estimated endogenous glucose production (EGP), glucose rate of appearance (Ra_{meal}) and glucose utilization (U) in T2D subjects (N=51). Lower panel: scheme of the T2D

simulation model. Metabolic fluxes are indicated with continuous lines, while control actions are represented by dashed lines. Adapted from [164].

TABLE 1. Oral Minimal Model Indices

Beta Cell Responsivity	
Dynamic Component Φ_d (10^{-9})	Amount of Dynamic Phase Secreted Insulin per Unit Increase of Glucose Concentration
Static Component Φ_s (10^{-9}min^{-1})	Over Basal Average Static Phase Secretion per Unit Over Basal Average Glucose Concentration
Delay T (min)	Delay between Static Phase Secretion and Glucose Concentration
Total Φ (10^{-9}min^{-1})	Overall Responsivity from Φ_d and Φ_s
Insulin Sensitivity	
Insulin Sensitivity S_I ($10^{-5}\text{dl}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$ per $\text{pmol}\cdot\text{l}^{-1}$)	Effect of Insulin to Stimulate Glucose Disposal and Inhibit Glucose Production
Disposal Insulin Sensitivity S_I^D ($10^{-5}\text{dl}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$ per $\text{pmol}\cdot\text{l}^{-1}$)	Effect of Insulin to Stimulate Glucose Disposal
Liver Insulin Sensitivity S_I^L ($10^{-5}\text{dl}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$ per $\text{pmol}\cdot\text{l}^{-1}$)	Effect of Insulin to Inhibit Glucose Production
Disposition Indices	
Dynamic Phase Disposition Index DI_d ($10^{-14}\text{dl}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$ per $\text{pmol}\cdot\text{l}^{-1}$)	$\Phi_d \times S_I$
Static Phase Disposition Index DI_s ($10^{-14}\text{dl}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$ per $\text{pmol}\cdot\text{l}^{-1}$)	$\Phi_s \times S_I$
Total Disposition Index DI ($10^{-14}\text{dl}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$ per $\text{pmol}\cdot\text{l}^{-1}$)	$\Phi \times S_I$
Hepatic Insulin Extraction	
Hepatic Extraction HE (%)	Average fractional secreted insulin extracted by the liver during the first pass

Figure 1

GLUCOSE MINIMAL MODEL

C-PEPTIDE MINIMAL MODEL

INSULIN & C-PEPTIDE MINIMAL MODELS

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7

Figure 8

Figure 9

Figure 10

Figure 11

Figure 12

Figure 13

Figure 14

A

B

Figure 15